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Cervical cancer screening guidelines have been revised, and now emphasize evidence-
based medicine, resulting in recommendations for less frequent screening; however, these 
changes have been met with concern by both patients and providers.  Understanding the 
patterns of acceptance versus reticence to accept these guidelines by health systems, 
providers, and patients is critical to developing successful strategies for translating policy 
change into routine practice.  Here we fill some of these knowledge gaps by 
incorporating both actual cervical cancer screening practice data and patient perspectives 
towards HPV testing and screening interval changes through the following specific aims: 
1a) describe the uptake of co-testing and examine the correlates of receiving an HPV co-
test, 1b) estimate the length of time until the next screening test following either a 
negative Pap smear alone or a dual negative co-test, and 2) investigate the correlates of 
reluctance to adhere to revised guidelines, which recommend the addition of HPV testing 
along with less frequent cervical cancer screening.   
 
Methods:  
Using cervical cancer screening records from the Pathology Data Systems (PDS) at Johns 
Hopkins Hospital, we estimate temporal trends in choice of screening strategy (cytology 
alone or with HPV DNA testing) and the interval between successive screening tests in 
routine clinical practice.  We then incorporate the patient perspective by using data 
collected in the HPV in Perimenopause (HIP) natural history study of women age 35-60 
years, we will compare women who indicate willingness versus reluctance to accept 
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alternative screening strategies such as HPV testing and a longer interval between 
cervical cancer screening tests.   
 
Results:  
In clinical practice, we saw a significant increase in use of HPV co-testing over the last 
10 years, reaching almost 80% of screening tests.  We also saw a significant increase in 
time between screening tests following a dual-negative co-test to almost 3 years, but 
essentially no change in time to next screening test following a normal Pap smear, 
remaining near 1.5 years.  Among patients, we found a majority of study participants 
indicated a willingness to adopt a cervical cancer screening strategy of cytology alone or 
Pap-HPV co-testing every 3 years if recommended by their physician, but remain 
concerned about primary HPV testing and co-testing with 5-year screening intervals.   
 
Conclusion:   
HPV testing was incorporated into screening with an assumption of less frequent 
screening due to its greater sensitivity and negative predictive value.  While intervals 
have increased following a co-test, more time will be needed to see whether they reach 5 
years as recommended.   We also found evidence of continued reticence to accepting 
newer HPV-based screening algorithms among routinely screened women over age 35, 
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Professional medical associations in the United States base screening guidelines and 
recommendations on systematic reviews of the evidence.  Recently, evidence-based 
review standards have begun to pay particular attention to the relative harms as well as 
benefits to screening.  This has led to a reduction in the overall recommended screening 
frequency for several cancer prevention strategies including breast, prostate, and cervical 
cancer screening.   In 2012, several organizations issued updated cervical cancer 
screening recommendations, emphasizing the need for less frequent screening and 
specifically advocating against the use of annual Pap smears (1-3).  These policy changes 
have been met with anxiety among both patients and providers.  Understanding the 
patterns of acceptance versus reticence to accept evidence-based guidelines by health 
systems, providers, and patients will be critical to development of successful strategies 
for translation of policy change into routine practice so that we can continue to prevent 
cervical cancer while minimizing the harms associated with screening.   
 
Here we attempt to fill some of these critical knowledge gaps by incorporating both 
actual cervical cancer screening practice data and patient perspectives towards HPV 
testing and screening interval changes. To do so, we used data from the Johns Hopkins 
Department of Pathology, Pathology Data Systems (PDS), and an ongoing cohort of 
women aged 35-60 years in routine gynecological screening who were enrolled in the 
HPV In Perimenopause (HIP) Study, to address the following questions: What are the 
current cervical cancer screening practices at Johns Hopkins and are they in line with 
contemporaneous evidence-based guidelines?  What is the knowledge of and attitude 
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towards changes in cervical cancer screening methods and frequency among women 




HPV and cervical cancer:  Infection with the human papillomavirus (HPV) is the 
primary cause of cervical cancer (4, 5). HPV is a double-stranded DNA virus in the 
papillomavirus family.  There are well over 100 known types of HPV, and they can be 
divided into two categories: oncogenic (high-risk) and non-oncogenic (low-risk).  
Oncogenic HPV types have been attributed to a range of cancers including cervical, 
vaginal, anal, and oral, while non-oncogenic types may cause a variety of warts.  The vast 
majority of HPV infections, however, are subclinical (6).  
 
HPV epidemiology: Approximately 40 of the HPV types are transmitted through sexual 
contact and can establish infection in the epithelial cells of the oral and anogenital tract 
(7, 8).  Approximately fourteen of these types are considered high-risk—able to be 
isolated from just about every cervical cancer.   Persistent infection with high-risk HPV 
strains may lead to the development of precancerous lesions and potentially invasive 
cancer, while some of the low-risk types can cause genital warts, though most do not 
cause detectable disease (5, 6, 9).  Two of the high-risk types, 16 and 18, cause 
approximately 70% of all cancers (10).   
 
Estimates suggest HPV is the most prevalent sexually transmitted infection among 
women in the United States (11), with high rates of infection following the onset of 
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sexual activity.  In a cohort of university women aged 18-20 years, cumulative incidence 
of HPV infection was over 40% within 3 years of sexual debut (12, 13).  Prevalence is 
highest in young women and then decreases though middle age, although a second peak 
in prevalence is seen around the age of menopause in many countries (14).  It is estimated 
that over 80% of women will be exposed to HPV in their lifetime (15, 16).  The majority 
of HPV infections are self-limiting, with over 80% of infections becoming undetectable 
within one to two years (6).  Persistently detectable HPV infections can lead to the 
development of high-grade lesions and invasive cancer if left untreated (6).   
 
Cervical cancer epidemiology: HPV is a necessary, but not sufficient cause of cervical 
cancer (4, 5).  The progression from infection to invasive cancer is slow, usually taking 
ten to fifteen years (17).  Nonetheless, because of the very high prevalence of high risk 
HPV in the population, cervical cancer is the 4
th
 most common cancer diagnosis and the 
2
nd
 leading cause of cancer mortality in women worldwide, with an estimated 528,000 
new cases and 260,000 deaths each year, over 85% of which are in the developing world 
(18).   
 
In countries with effective screening programs, invasive cervical cancer (ICC) rates are 
much lower.  Estimates suggest that there will be almost 12,400 new cases of cervical 
cancer and a little over 4,000 cervical cancer deaths in the United States in 2014.  In the 
US, the age-adjusted incidence rate is 7.8 per 100,000 women per year (up to 18.6 per 
100,000 after hysterectomy adjustment (19)) and the mortality rate is 2.4 per 100,000 
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women per year.  These rates have been on the decline for over 40 years largely due to 
successful, widespread implementation of routine screening (20).   
  
Cervical cancer prevention: Unlike many other cancers, cervical cancer is entirely 
preventable as there are highly effective primary and secondary prevention strategies 
available.  Two vaccines have been licensed for the prevention of HPV infection, both of 
which prevent infection of the two HPV strains (types 16 and 18) that cause 70% of 
cervical cancer cases.  Merck’s quadrivalent Gardasil vaccine protects against low-risk 
HPV types 6 and 11, which cause genital warts, in addition to the high-risk strains 16 and 
18, and was first licensed by the FDA in 2006 (21).  GlaxoSmithKline’s bivalent 
Cervarix vaccine prevents against HPV types 16 and 18, and was licensed by the FDA in 
2009 (22).   Gardasil is approved for use in males and females ages 9-26 years, while 
Cervarix is approved for use in females ages 9-25 years.  Both vaccines have shown over 
90% efficacy in protecting against their intended strains (23, 24).   
 
However, the vaccines are only effective at preventing infection in HPV-naïve 
(unexposed to the vaccine strains), which is why vaccination is recommended prior to 
sexual debut.   Since vaccines were only introduced starting in 2006, and showed slow 
uptake (<35% coverage of eligible females in the first 5 year), many women remain 
unvaccinated and therefore need to continue routine cervical cancer screening (25).  
Women vaccinated shortly after vaccine approval but after sexual debut may have 
already been exposed to high-risk strains, and so they also need to continue screening.  
Lastly, even among those vaccinated early, these vaccines only protect against the 2 
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strains that cause 70% of cervical cancer cases, so women remain at risk for developing 
cervical cancer from the other high-risk strains.  Newer HPV vaccines are also under 
development, which aim to prevent against 9 of the high-risk strains, and so would offer 
greater protection as well.  However, continued secondary prevention of cervical cancer 
through routine screening programs will remain important at least until screening 
populations are fully vaccinated. As both primary and secondary prevention options 
improve, cervical cancer rates will continue to fall, and thus the efficiency of screening 
becomes even higher priority.   
 
Evolution of cervical cancer screening: Since its development in the 1940s, screening 
for cervical cancer has been based primarily on morphologic examination of cervical 
cytology specimens, or Pap smears (26).  However, recognition that HPV is the necessary 
cause of cervical cancer has led to the development of newer screening technologies 
based on detection of biological markers of HPV infection.  As our understanding of 
HPV and cervical cancer evolves, so do our screening options, requiring frequent 
updating of our tools and the guidelines for their use.   
 
Pap smears: The Pap smear is a screening test used to detect cervical cancer and its 
precursors, and was first described by Dr. George Papanicolaou in the 1920s, but didn’t 
gain widespread use until the 1940s.  Dr. Papanicolaou discovered that he could detect 
abnormal cells on a vaginal smear, thus providing a relatively cheap and less invasive 
way to screen for cancer on a large population than performing biopsies (26, 27).    
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As a result, Pap smears, also referred to as cervical cytology, have been in wide use in the 
United States for over 50 years and is the most frequently used cancer screening test.  Pap 
smears are credited with over a 50% reduction in cervical cancer over the past 30 years 
(20). In 2012, 78% of women over age 18 in the US reported having a Pap smear in the 
last three years (28).    
 
The test is performed by a trained health care provider during a speculum examination.  
The physician or nurse collects exfoliated cervical cells using a small brush or other 
collection device.  The sample is then placed on a glass slide and preserved with a 
fixative so it can be sent to a laboratory to be evaluated.  Results will indicate whether or 
not abnormal cells were detected, and if so, the type or degree of abnormality detected 
(29).  Cytology has a sensitivity in the range of 50-80% for high-grade disease and 
around 50% for low-grade disease, and specificity of 85-100% (30-32).  
 
Since its initial discovery, the method has evolved from conventional cytology to liquid 
based cytology (LBC), a more automated process.  For LBC, the sample is placed into a 
container with a preservative fluid instead of smeared on a slide.   Once in the laboratory, 
a machine transfers a layer of cells onto a slide for analysis (29).  This method is 
comparable in terms of sensitivity and specificity, but is an improvement over 
conventional Pap smears in that it reduces the number of inadequate or unsatisfactory 
results (33, 34).  The residual fluid can also be used for HPV DNA testing, without 
requiring an additional sample.  In the US, LBC is now the primary method of cervical 
cancer screening in use.   
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HPV DNA testing: The discovery that HPV is the necessary cause of cervical cancer has 
led to the development of newer screening methods that can identify an HPV infection by 
detecting the presence of HPV DNA or other molecular markers of HPV infection in a 
sample of cells from the cervix.  The first HPV DNA test was approved for clinical use in 
the United States in 2003.  This Hybrid Capture 2 (hc2) test can detect the presence of 
any of 13 high-risk and 5 low-risk HPV types, but is not type specific and does not 
distinguish which of the genotypes are present (35).  More recently, the US FDA 
approved the first HPV test for an indication of primary HPV only screening (36).   
 
Approval of new screening tests meant that they needed to be evaluated for evidence-
based application in cervical cancer screening programs.  Multiple uses of HPV tests 
have been evaluated and approved by the FDA, including ASCUS triage, HPV alone as a 
primary screen, and co-testing in conjunction with Pap tests.  ASCUS triage with HPV 
testing means that only those Pap results that come back as ASCUS will be followed up 
with testing to look for the presence of HR-HPV.  This method has a sensitivity and 
specificity of approximately 91% and 62% for CIN2+ and 95% and 60% for CIN3+.  As 
a primary screening test, HPV testing had high sensitivity (90% or higher), but specificity 
varied by setting from 50-100% for high-grade disease (37).  Co-testing involves the use 
of an HPV test along with a Pap smear, increasing both the sensitivity and negative 
predictive value of the screening result, thus safely allowing for longer intervals between 
screening in dual negative women.   Co-testing is only recommended for women 30 years 
of age and older, as the test is less specific for precancerous lesions due to the higher 
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prevalence of HPV in younger women.   Reflex testing of ASCUS Pap results is 
recommended in all women.   
 
Potential harms of screening: While the benefits of cervical cancer screening are 
obvious, the potential harms are less so, but are important nonetheless.  The slow 
growing nature and long detectable precancerous period of cervical cancer provide ample 
opportunity for early detection (38-40).  Since many HPV infections and precancerous 
lesions resolve on their own, screening too frequently will lead to detection of transient 
abnormalities, causing the potential for psychological trauma and overtreatment of 
regressive lesions (38, 41-44).  Continued follow-up and treatment of these abnormal 
results is costly in terms of both time to the patient and for the procedures being done.  In 
addition to more frequent follow-up appointments, over-screening can lead to false 
positives resulting in colposcopies and either excisional (ie: loop electrosurgical excision 
procedure (LEEP)) or ablative (ie: laser, cryotherapy) treatment.  Furthermore, these 
procedures carry risks of their own, such as infection, as well as other long-term 
consequences such as adverse pregnancy outcomes including increased risk of pre-term 
delivery.  Thus when performed for an abnormal result that would otherwise clear on its 
own, the harm outweighs the benefit (45-47).  It was the need to balance these harms with 
the benefits of screening, combined with newer knowledge about HPV natural history 
and study data indicating comparable benefits with less frequent screening, that has led to 
the need to revise screening interval guidelines (1, 2).   
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Changes to cervical cancer screening guidelines: While annual screening with Pap 
smears remained the norm in the United States for decades following its introduction, 
over the last decade or so, professional medical and public health organizations have been 
revising their cervical cancer screening guidelines, with little consensus until the recent 
2012 guidelines.   
 
Table 1.1:  Summary of routine screening guidelines for women age 30-65 by  
 
organization since 2002  (see next page) 
 
 
Updated screening recommendations: In 2012, the US Preventive Service Task Force 
(USPTF), American Cancer Association (ACS), American Society for Colposcopy and 
Cervical Cytology (ASCCP), and American Society for Clinical Pathology (ASCP) 
updated their joint guidelines for cervical cancer screening, specifically recommending 
against annual screening using any strategy.  Cytology alone at 3-year screening intervals 
and HPV co-testing with cytology at 5-year intervals were both considered acceptable 
strategies for women aged 30-65 years (1, 2).  These recommendations were made 
following a thorough review of available data and concluded that the harm from 
unnecessary follow-up of regressive disease outweighs the benefit (45, 46), when 
comparing annual to every 3 year screening (1, 2).  The American College of 
Obstetricians and Gynecologists (ACOG) updated their guidelines shortly thereafter, 
recommending Pap-HPV co-testing over age 30 at a 5-year interval as the preferred 
method, but cytology every 3 years as acceptable (3).  While primary screening with 
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ACS ACOG ASCCP** USPSTF 
Pre-2003 
Yearly Pap test, but after 3 
consecutive normal 
exams, less frequently at 
the discretion of the 
doctor 
Yearly Pap test 
Annual or Bienniel Pap 
smears 
Pap test at least every 3 
years, but no benefit to 
annual Paps 
 
(48) (49) (50) (51) 
2003-2009 
Age 30+: after 3 normal 
Paps in a row- can move 
to every 2-3 years; OR 
screen every 3 years with 
Pap/HPV co-test 
Age 30+: after 3 normal 
Paps in a row- can move 
to every 2-3 years; OR 
screen every 3 years with 
Pap/HPV co-test 
2004: Okay to co-test 
every 3 years 
Pap test at least every 3 
years, but no benefit to 
annual Paps, insufficient 
evidence to recommend 
co-testing 
 
(48, 52)  (53) (54) (55) 
2009-2012 No change 
Age 30+:  Pap every 2 
years; OR after 3 
consecutive negative Paps 
can be screened once 
every 3 years 
No change No change 
 




Age 30-65: Pap test every 
3 years or Pap/HPV co-
test every 5 years* 
Age 30-65: Pap test every 
3 years or Pap/HPV co-
test every 5 years* 
Age 30-65: Pap test 
every 3 years or 
Pap/HPV co-test every 
5 years* 
Age 30-65: Pap test 
every 3 years or 
Pap/HPV co-test every 5 
years 
  (1, 48) (3) (1) (2) 
 
*Cytology only acceptable, Co-test preferred method 
 
 
**guidelines primarily for abnormal cytology until 2012 
 
Table 1.1: Summary of cervical cancer screening guidelines for women age 30-65 by 
organization over time 
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HPV testing was not recommended in the 2012 guidelines, in April 2014 the US Food 
and Drug Administration (FDA) approved the Roche cobas® HPV test for a primary 
screening indication (36), and interim guidelines for use of an HPV only strategy are 
anticipated. 
 
Current screening practices:  Given the different cervical cancer screening guidelines 
that have been issued over the last 10-15 years, it is not immediately clear which of the 
alternative screening methods are being used and whether they are being employed as 
recommended (52, 56).  There is no mandate for providers to adhere to evidence-based 
guidelines, and there is ample evidence to suggest a general lack of adherence to the 
published guidelines.  Both focus groups and nationally representative surveys of 
physicians have shown that doctors frequently recommend cervical cancer screening 
more often than indicated by the guidelines (57-59).  In addition to frequent reports of not 
extending screening intervals where appropriate, physician report of non-evidence based 
screening practices such as low-risk HPV DNA testing, HPV testing in women under 30, 
and HPV testing after an ASC-H or HSIL Pap result have been commonly documented 
(60-64).  Clearly there is wide variation in screening recommendations and practices at 
the provider level.  
 
Most studies about physician knowledge and adherence to guidelines have been based on 
self-report or response to vignettes and not on actual practice (57-60, 62-64).  While data 
showing physician intentions for screening recommendations are important, we must also 
consider what is actually being done in practice.  Two recent studies of a large academic 
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medical center showed slow uptake of new screening practices, with rates of co-testing 
plateauing around 15% for women over 30 from 2006 through 2008 before increasing to 
about 40% between 2008 and 2010.  Within this single institution, rates of co-testing 
varied greatly by clinic. There was also indication of non-evidence based practices 
including HPV testing in women under 30 and repeat testing within 3 years of a dual-
negative (65, 66).  Similar trends were seen in data from other reference laboratories and 
academic primary care settings (67, 68), with one study showing that 66% of women who 
were eligible for extended screening intervals had unnecessary screening tests performed 
between 2008 and 2009 (69).   
 
Now that consistent screening guidelines are in place, it is important to evaluate whether 
these new consensus recommendations are being adopted.  Although the 
recommendations are based on strong evidence from randomized controlled trials 
comparing cytology alone to HPV co-testing, providers faced with choosing between 
these options are calling for more direct “real-world” evidence of the harms and benefits 
of alternative screening strategies.   As the newest evidence suggests HPV tests are the 
superior screening method, eventual displacement of Pap by HPV testing as a primary 
screening method is possible.  Thus, it is important to evaluate whether HPV testing is 
being incorporated into routine practice, screening intervals are simultaneously being 
extended, and if there is population variability in HPV test utilization.  Increases in co-
testing frequency without interval lengthening may result in increasing, rather than 
decreasing, costs to patients and the health care system.   
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 Table 1.2:  Summary of publications examining physician recommendations and 
clinical practices (see next page) 
 
Patient attitudes towards new recommendations: Adherence to evidence-based 
screening is influenced not just by provider practice.  If the nuanced message explaining 
the reasoning behind less frequent screening is not conveyed clearly to the public, it is 
unlikely that this policy will be effectively translated into practice.  People may see it as 
unsafe or a means to ‘ration care’ rather than an evidence-based decision (70, 71), as was 
the case with the breast cancer screening guideline changes in 2009 (72, 73).  
Additionally, patient anxiety and expectation of having a screening test has been shown 
to influence a provider’s screening recommendation (74). As a result, it is important to 
more fully understand how news of these updated guidelines is received by women and 
whether that influences their (and their provider’s) decisions about screening frequency 
(71, 74, 75).    
 
Evidence suggests that the public is resistant to being screened less frequently (70, 76, 
77), and the preference for annual screening compared to less frequent screening has been 
demonstrated repeatedly (62, 70, 71, 78).  For example, Australian women reported a 
preference for annual Pap smears despite a national policy of biennial screening, citing 
early detection and peace of mind as the primary motivation behind their preference (79).  
Similarly, a survey of racially and ethnically diverse women in San Francisco reported 
that a third of women between the ages of 50 and 65 wanted annual Pap testing after 
dual-negative co-testing, and almost half of women over age 65 indicated the same (78). 
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Author Year  Study Design Study Population or Data 
Source 
Findings 
Phelan 2011 (65) Pap and HPV pathology 
clinical screening results 
178,510 Johns Hopkins 
Hospital Pathology records 
between 2001-2007 
High uptake of reflex by 2007, co-test 
uptake remained low around 15% in 
2008 
Tatsas 2012 (66) Pap and HPV pathology 
clinical screening results 
Johns Hopkins Hospital 
Pathology records 2008-
2010 
Co-tests reached 40% by 2010, large 
differences in co-test rates by clinic 
Cooper 2005 (57) 13 qualitative telephone 
focus groups asking about 
guideline knowledge and 
screening practices (self-
report) 
69 physicians in 17 states 
and DC  
In 2002/2003, no physicians were 
familiar with NBCCEDP's (National 
Breast and Cervical Cancer Early 
Detection Program) trienniel Pap 
policy and none routinely extended 
intervals, even though policy had been 
in place for over a year at the time of 
study 
Berkowitz 2010 (58) Cross-sectional nationally 
representative survey using 
clinical vignettes for a 35 
year old woman (self-
report) 
Nationally representative 
sample of 950 physicians 
Most physicians (87.8%) did not 
adhere to guideline recommendations 
for mildly abnormal results or 
discordant results (45.7%), 




2005 (80) Cross-sectional mailed 
survey to assess guideline 
knowledge and clinical 
vignettes to assess practice 
preferences (self-report) 
136 physicians in a large 
university affiliated practice 
associated with an HMO in 
Central Texas 
Based on vignette response, 57.4% of 
physicians were found to adhere to 
published guidelines, but wide 
variations exist; physicians were 
uncomfortable lengthening the interval 




in low-risk patients with negative 
screening history 
Mathias 2012 (69) Electronic health records of  
Pap tests and colposcopies 
Non high-risk women 30-65 
years with a normal Pap 
during 2007 at the 
Northwestern Medical 
Faculty Foundation Clinic 
65.7% of women receive a Pap smear 
soon than recommended following a 
history of normal results in 2008 or 
2009, with 25.3% receiving them in 
both years (instead of every 3) 
Roland 2011 (62) Cross-sectional nationally 
representative survey of 
self-reported screening 
practices and response to 
clinical vignettes 
Nationally representative 
sample of 376 physicians 
<15% of providers who ordered an 
HPV test recommended the next 
screen in 3 years, recommending 1 
year instead in 3 clinical vignettes 
Saraiya 2010 (63) Mailed survey to a 
nationally representative 
sample of physicians 
Representative sample of 
950 primary care physicians 
Fewer providers recommended 
extending intervals to 3 with an HPV 
co-test (19%) than with a Pap test 
alone (32%) 
Meissner 2010 (59) Nationally representative 
survey of physicians using 
a clinical vignette 
Nationally representative 
sample of 1114 primary care 
physicians who perform Pap 
smears 
32% of physicans had adopted a 3-year 
interval, factors associated with less 
frequent screening included serving a 
higher proportion of Medicaid patients 
Lee 2011 (60) Cross-sectional survey of a 
nationally representative 
sample of Pap test 
providers 
376 office-based healthcare 
providers and 216 outpatient 
clinics 
Of the providers who offer HPV 
testing (75%), 29% also used low-risk 
tests; Most providers performed co-
testing in women under 30 and also 
performed HPV reflex after ASC-H 
and HSIL 
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Moriarty 2008 (61) Used data from the College 
of American Pathologists 
Supplementary 
Questionnaire in 2006 
679 laboratories 45% of labs offered low-risk HPV 
testing despite lack of clinicial 
signficance; many clinics used HR-
HPV reflex testing used in non-
recommended situations (ASC-H: 
48%, LSIL: 28%, HSIL: 22%, AGC: 
20%); Co-testing in women over 30: 
25% 
Yabroff 2009 (64) Cross-sectional nationally 
representative survey 
assessing knowledge, 
attitudes, and practices 
related to cervical cancer 
screening using mailed 
questionnaire with clinical 
vignettes 
Nationally representative 
sampler of 1212 primary 
care physicians 
On a composite measure (combining 
all4 vignettes) ~20% had guideline 
consistent recommendations for 
screening frequency; large range by 
physician specialty and vignette- 
range: 25%-65% individual vignettes 
for women over 30 
Shirts 2010 (67) Retroactive analysis of 
laboratory test ordering 
patterns 
454,532 HPV tests ordered 
between Sept 2003 and Oct 
2009 from 110 laboratories  
Decrease in non-recommended HPV 
testing among women under 30; only 
6% of repeat HPV tests in women over 
30 followed a 3-year interval 
Thrall 2010 (68) Computerized laboratory 
records for University of 
Rochester Medical Center 
were reviewed from Jan 1, 
2006, to Dec 31, 2006 
All (N=2719) Pap tests 
performed during 2006 at 
URMC with NILM results 
and HPV co-testing 
Almost half of dual-negative women 
received another screen within 18 
months, which is not consistent with 
guidelines (too frequent) 
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A nationally representative survey of women in the US in 2005 found that almost 80% 
thought a woman should have a Pap smear every year, but almost two-thirds were willing 
to extend screening to every three years if their provider recommended it (59).  
 
Table 1.3:  Summary of publications examining patient attitudes toward changes in 
cervical cancer screening (see next page) 
 
 19 





Study Population or 
Data Source 
Findings 
Sirovich 2005 (70) 
 
Random digit dialing telephone 
survey in 2002 about 
acceptance of less intense 
screening 
Nationally representative 
sample of women age 
40+ with no cancer 
history 
75% of women preferred to be screened 
annually; less than half had heard about 
recommendations for less frequent 
screening; 69% would try to be screened 
annually even if heir doctor 
recommended less frequent screening 
Dieng 2011 (79) 
 
 
Structured telephone interview 
about testing preferences, 
information and decision 
making needs 
Random sample of 1279 
Australian women 
between 18 and 70 years 
50%of women preferred having Pap 
smears at least annually, 38% every 2 
years; 85% wanted concurrent HPV 
testing 
Ashok 2012 (81) 
 
 
Data from 2007 Health 
Information National Trends 
Survey (HINTS) 
2915 female respondents 
between age 18-64 
65% had been screened within 1 year; 
81% of women expected to be screened 
again within a year 





Telephone and in-person 
interviews about awareness of 
HPV, preferences for HPV 
testing 
865 diverse women 
between 50 and 80 years 
60% wanted to be tested for HPV and 
another 15% would be tested if 
recommended by their physician; of 
those willing to be tested- 55% would 
accept 3 year intervals, 12% more 
would if recommended by doctor, 
remaining 33% would still want annual 
screening 
 20 
Meissner 2010 (59) Data from the 2005 Health 
Information Trends Survey 
(HINTS) a bienniel telephone 
survey 
Nationally 
representative sample of 
2206 women eligible for 
Pap screening 
Women were more willing to follow a 
3-year interval if the were older, less 
willing if they had personal/family 
cancer experience or followed an 
annual Pap test schedule 
Cooper 2011 (82) 15 focus groups in 4 major US 
cities to understand their 
awareness and knowledge of 
screening and risk factors for 
gynecologic cancers 
132 women aged 40-60 Some misunderstood about what a Pap 
test screens for and thought it was all-
inclusive for other cancers, STDs, etc; 
strong emphasis on the benefit of early 
detection; Very few were aware of 
extended intervals, and when 
mentioned, many reacted negatively 




8 focus groups with semi-
structured interviews to explore 
attitudes, beliefs and barriers to 
cervical cancer screening 
58 diverse women over 
18 years old 
Women were not open to the idea of 
reducing Pap screening frequency 
because they perceive annual screening 
to be an effective screening method 
Rolnick 1999 (75) 
 
 
Mailed survey to random 
sample of women within a large 
health maintenance 
organization about Pap smear 
history and perceptions of the 
new guideline (trienniel 
screening)  
673 women between ages 
20-69 
63% had no recollection of being 
informed about the guideline change, 
14% responded positively to the change 
while 50% responded negatively 
Sirovich 2004 (77) 
 
Data from the National Health 
Interview Survey (NHIS), a 
cross-sectional population-
based telephone survey 
16467 women age 21 or 
older with no history of 
cancer 
93% had at least 1 Pap smear, 55% were 
screened annually, 17% every 2 years, 
16% every 3 years, 11% not regularly 
screened, (>70% screened more 




United States cancer screening guidelines are based on systematic reviews of the 
evidence conducted at the behest of professional medical and public health associations.  
Recently, evidence-based review standards have begun to give a proportionate weight to 
evaluation of the harms relative to benefits of a given cancer screening strategy.  In this 
context, screening guidelines have been revised for several cancers, including breast, 
prostate, and cervical cancer, often recommending less screening compared with 
previous guidelines.  Such evidence-based recommendations can be misinterpreted by 
the public as a means to ration care rather than to provide the safest and most effective 
screening strategy.  Such misperceptions by the targeted screening population 
regarding the policy change are significant barriers to rapid and effective 
translation of evidence-based guidelines to clinical practice.   
 
For cervical cancer, the most recent guidelines recommend routine screening every 3-5 
years, which is at odds with the common practice of annual Pap smears.  In our study of 
perimenopausal women attending routine gynecological care in the US between 
2008 and 2012, 80% believed cervical cancer screening should be performed at least 
once per year, and 50% were not willing to reduce the frequency of screening even if 
recommended by her physician.  We hypothesize that this reluctance to accept 
evidence-based guidelines will delay compliance with the revised cervical cancer 
screening guidelines, and that women expressing reluctance to accept extended screening 
intervals can be differentiated from women accepting revised guidelines according to the 
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following characteristics: a) more likely to have a higher perceived cervical cancer risk 
and 2) report a higher compliance with other prevention services (e.g., the worried well). 
 
To address these hypotheses and to gain further insight into the attitudes and behaviors of 
patients which limit their compliance with screening guidelines, we propose the 
following specific aims: 
 
SPECIFIC AIM 1: To examine trends in cervical cancer screening practices from 2001-
2013 in a large academic medical center.   
Using data from the Pathology Data Systems at Johns Hopkins Hospital, we will 
estimate temporal trends in choice of screening strategy (cytology alone or in 
combination with HPV DNA testing) and frequency of screening.  
 
SPECIFIC AIM 2: To investigate the correlates of reluctance to adhere to revised 
guidelines, which recommend less frequent cervical cancer screening.   
Using data collected in the HPV in Perimenopause (HIP) natural history study of 
women age 35-60 years, we will compare women who indicate willingness versus 
reluctance to accept a longer interval between cervical cancer screening tests by the 
following factors: demographics, age, health status, cervical cancer screening 
history, sexual history, perceived HPV and cervical cancer risk, and participation in 
preventive health programs.  This cohort offers a unique opportunity to address this 
aim by allowing simultaneous evaluation of women’s self-reported perceived risk 
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and their actual risk of cervical cancer based on intensive measurement of HPV and 
cervical cancer risk markers over a 2-year period. 
 
Evidence-based recommendations are valuable only if broadly implemented in routine 
clinical and public health practice.  However, key components to effective translation, 
including the perceptions and acceptance of screening recommendations, are often 
absent from the evidence.  This proposal is designed to address this gap by using 
mixed methods to provide a comprehensive assessment of the uptake of 
recommendations in a large academic medical center and identify potential patient-
specific characteristics which may affect efficient translation.  We will provide much 
needed data on psychosocial impact of changes in screening guidelines, which are critical 
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Chapter 2: HPV test utilization increasing in 
routine screening of women over age 30 years: 





Objective:  HPV DNA tests have been approved for routine use for over a decade, and 
their use will likely continue to increase.  As the newest evidence suggests they are the 
superior screening method, eventual displacement of Pap by HPV testing as a primary 
screening method is possible.  Thus, it is important to evaluate not just patterns of use, 
but also whether there is population variability in HPV test utilization.  In this analysis, 
we describe the uptake of co-testing in Johns Hopkins Hospital System affiliated clinics 
between 2006 and 2013 as well the correlates of receiving an HPV co-test during this 
period.   
 
Methods: This analysis included 55,575 Pap and HPV test records from 27,035 women 
screened through from the Johns Hopkins Hospital (JHH) Pathology Data System (PDS) 
between 2006 and 2013.  Using this data, we estimated co-test uptake by year and by 
clinic.  Prevalence ratios for co-testing by age and race by insurance categories were 
calculated by time period using adjusted multivariate log-binomial models with robust 
standard errors.  To account for the clustering of observations within clinics, these same 
models were run with the addition of a random-effect variable for clinic.   
 
Results: Co-test rates increased from below 10% in 2006 to a mid-year peak of 78% in 
2013.  Despite high rates of co-testing in recent years, the distribution of co-test uptake 
among clinics and subgroups varied across the entire period.  Co-testing proportions were 
highest among younger women, black women, and women with Medicaid.  Furthermore, 
rates of co-testing were consistently higher among black women for all insurance types 
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other than Tricare.  Once the model was further adjusted for the difference in clinic-level 
practices using a cluster term, we no longer saw an effect of age, race, or insurance on co-
test prevalence.  The initial differences seem to be largely explained by demographic 
differences among clinics with higher co-test frequencies than those with lower 
frequencies.   
 
Conclusion: In the earlier time periods, a greater proportion of the predominantly black 
clinics had high rates of co-testing, indicating that these clinics may be earlier adopters of 
co-testing as compared to the predominantly white clinics.  This difference by race and 
insurance type clustered within clinics, and demographic differences between clinics with 
higher versus lower co-test frequency appear to be a potential explanation for these 
differences.  These clinic level differences attenuated significantly over time, suggesting 
that clinics with underserved minority and government insured populations were the 




Rates of cervical cancer in the United States have dropped by over 50% in the last 30 
years due to a high proportion (>80%) of women participating in routine Pap smear 
screening programs (1, 2).  As scientific knowledge regarding the natural history of 
cervical cancer, and its necessary cause- the human papillomavirus (HPV) have evolved, 
guidelines for these screening programs have changed to incorporate the new science.  
The first HPV DNA test was approved by the FDA in 2003 for use in routine cervical 
cancer screening for women over age 30, and was incorporated into select screening 
recommendations soon after (3-6).   
 
Previous studies have shown that uptake of HPV testing as a reflex for mildly abnormal 
Pap smears occurred rather quickly, with almost complete adoption in some locations 
within 5 years (7-9).  However, following the FDA approval of the Digene hc2 test for 
co-testing women over 30 years of age, the addition of HPV testing to Pap smear 
screening visits occurred much more slowly, with reports of less than 40% uptake in 
2010 (9-11).  In 2012, several professional screening organizations revised their 
screening guidelines to emphasize both HPV testing and the need for less frequent 
screening.  In their joint guidelines, the American Cancer Association (ACS), American 
Society for Colposcopy and Cervical Cytology (ASCCP), and American Society for 
Clinical Pathology (ASCP) as well as the American College of Obstetricians and 
Gynecologists (ACOG) all recommended Pap/HPV co-testing with a 5-year screening 
interval as the preferred screening method (12, 13).  Likewise, in 2012, the US Preventive 
Services Task Force (USPSTF) also issued revised screening guidelines that 
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recommended cytology every three years or co-testing every 5 years for woman who 
want a longer screening interval (14).  More recently, the FDA approved the Roche 
Cobas HPV test for an additional indication of primary, stand-alone cervical cancer 
screening (15).   
 
Now that HPV DNA tests have been approved for routine use for over a decade, their use 
will likely continue to increase.  As the newest evidence suggests they are the superior 
screening method, eventual displacement of Pap by HPV testing as a primary screening 
method is possible.  Thus, it is important to evaluate not just patterns of use, but also 
whether there is population variability in HPV test utilization.  In this analysis, we 
describe the uptake of co-testing in Johns Hopkins Hospital System affiliated clinics 
between 2006 and 2013 as well the correlates of receiving an HPV co-test during this 




Data source and data collection 
 
This analysis used data obtained from the Johns Hopkins Hospital (JHH) Pathology Data 
System (PDS), and included all Pap smear and HPV tests processed by the Pathology 
Department between January 1, 2001 and May 28, 2013.  PDS is an in-house clinical 
database routinely used by the Pathology Department to collect and store test results.  It 
contains results of any sample processed by the Hopkins Pathology Department, which 
receives samples from over 200 clinics in and around the Baltimore area.  Records were 
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obtained through a data use agreement with Johns Hopkins Hospital Systems, and a 
limited dataset was created to replace medical record numbers with a unique patient 
identifier.  The dataset included a patient identifier, patient age, race, insurance type, date 
of sample collection, date of test, test result, diagnosis, ordering physician and clinic 
where the patient was seen. All study procedures were approved by the Johns Hopkins 
Bloomberg School of Public Health Institutional Review Board.   
 
Pap smear and HPV test results were extracted from the free text diagnosis variable by 
searching for expressions or strings of words.  For this analysis, all Pap smear results 
were coded as normal (or no intraepithelial lesion or malignancy, NILM), atypical 
squamous cells of undetermined significance (ASCUS), low-grade squamous 
intraepithelial lesion (LSIL), atypical squamous cells- cannot rule out high grade lesion 
(ASC-H), high-grade squamous intraepithelial lesion (HSIL), carcinoma (cancer), or 
atypical glandular cells (AGUS) based on the most severe diagnosis in the text field. 
HPV testing was performed using the Digene hc2 test according to manufacturer’s 
instructions (Qiagen, Gaithersburg, MD) and results coded as negative (relative light unit 




We received all Pap smear and HPV test results in PDS processed between January 1, 
2001 and mid-2013 (N=306,722 records), and then applied several restrictions to the data 
as described in Figure 2.1.  For the initial data cleaning step, we eliminated records with 
male or unknown sex, samples collected prior to January 1, 2001, duplicate records, and 
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records without a Pap smear result.  We then restricted our dataset to include only 
samples collected from clinics likely to be performing routine screening (excluding 
specialty locations such as colposcopy and HIV clinics).  Given our aim of estimating 
HPV co-test uptake, we performed our analysis only among women of routine screening 
age who were eligible for HPV co-testing (ages 30-65), starting in 2006 when co-test 
prevalence first began to increase. 
 
Insurance was characterized by type of provider: private (including HMOs, PPOs, Blue 
Cross), Medicare, Medicaid, and Tricare (military), and any records without an insurance 
code or with an insurance code that could not be verified were excluded.  To eliminate 
any HPV testing as a follow-up to a prior abnormal result and not as part of routine 
screening, we restricted our analyses to routine screening tests, which were defined as a 
test performed at least 300 days after a prior screen.  This restriction necessarily meant 
that only women with at least 2 records were included in this analysis.  Additionally, 
because there was no consistent code to indicate whether a co-test was ordered, we 
restricted the analysis to normal Pap results where there would be no other indication for 
HPV testing other than as a co-test, and thus co-tests were defined as any visit with a 
negative Pap smear that included an HPV test, and 92.6% of screening records fell into 
this category.  
 
The percent of all screening visits that included a co-test were calculated by year, age, 
race, and insurance category, and were stratified by time period. Percent co-testing and 
percent black race at each clinic were calculated and graphed by time period, with scaling 
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of circle size according to the number of screening tests performed at each clinic.  
Prevalence ratios for co-testing by age and race by insurance categories were calculated 
by time period using adjusted multivariate log-binomial models with robust standard 
errors.  To account for the clustering of observations within clinics, additional models 
were run including a random-effect variable for clinic.  All analyses were performed in 






The restricted dataset for this analysis included 55,575 records from 27,035 women of 
routine screening age who were eligible for HPV co-testing (30 to 65 years of age) 
between 2006 and mid-2013 (Table 1).   These women had a median age of 47 years 
(interquartile range (IQR): 38-55).  Overall, this group was 51% white, 36% black, and 
13% other races.  Seventy percent had private insurance, 8% had Medicare, 13% 
Medicaid, and 10% had Tricare (military) insurance. 
 
Uptake of Pap/HPV co-testing instead of cytology alone 
 
Following the approval of HPV co-testing for use in routine screening, initial uptake of 
co-testing in the Johns Hopkins System was low (below 5% through 2005), but it has 
significantly increased since that time (Figure 2.2).  Co-testing increased almost 9-fold, 
from 8.85% in 2006 to 78.35% in mid-2013. The overall proportion of co-testing during 
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this time was about 35%, but the distribution of co-test uptake among subgroups varied 
across the entire period.  Co-testing proportions were highest among younger women, 
black women, and women with Medicaid.  Furthermore, rates of co-testing were 
consistently higher among black women for all insurance types other than Tricare.   
 
To account for the significant effect of time on co-test uptake, we stratified our data into 
3 time periods based on the recommendations in place at that time:  2006-2008 was when 
co-testing was first incorporated into guidelines and so co-test use was low (5-25%), 
2009-2011 was when guidelines continued to add co-testing to their recommendations 
and co-test use was moderate (25-50%), and 2012-2013 when the new consensus 
guidelines were put in place and co-testing rates increased (>50%).  While differences in 
the distribution of co-testing among sub-groups remained through each time period, the 
magnitude of those differences diminished with time as co-testing became more prevalent 
overall (Table 2.1).  The average percent of co-test samples during the 3 time periods 
were 12.61%, 42.18%, and 61.25%, respectively.   
 
Despite this overall trend of increasing rates of co-testing in this system, tremendous 
variability existed on a clinic-by-clinic basis (Figure 2.3).  There were clinics in the 
earliest years with rates over 50% and clinics in the most recent years with rates of co-
testing remaining below 10% in some clinics, while reaching almost 100% in others.  We 
explored whether these differences in clinic practices could account for the differences 
seen among sub-groups by examining the distribution of race by clinic (Figure 2.3).  In 
addition to showing the general trends of increasing co-test uptake, they also demonstrate 
 45 
that uptake differed by racial make-up of the clinics.  In all three time periods, a greater 
proportion of the predominantly black clinics had high rates of co-testing, indicating that 
these clinics may be earlier adopters of co-testing as compared to the predominantly 
white clinics.   
 
Prior to accounting for clinic-level differences, co-test prevalence decreased significantly 
by age, even after mutually adjusting for the effects of race and insurance, with older 
women less likely to be co-tested than younger women.  However, the differences by age 
decreased over time (Table 2.2).  Once the model was further adjusted for the difference 
in clinic-level practices using a cluster term, we no longer saw an effect of age on co-test 
usage.  Similar findings were seen for the insurance by race categories—while significant 
differences were seen among many of these categories, most notably in the earliest time 
period, those differences diminished over time, and seem to be largely explained by 
demographic differences among clinics with higher co-test frequencies than those with 




Cervical cancer screening recommendations have had to evolve over the last fifteen years 
to keep pace with scientific knowledge and technologic advancements.  First, there was 
the addition of ViraPap to conventional cytology, then the transition to liquid-based 
cytology and more recently the incorporation of HPV DNA testing, as either a reflex or 
co-test (and soon as a primary test) (3, 4, 6, 16).  While screening guidelines are an 
important driver of clinical practice, they are not a mandate.  Despite the fact that the 
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recommendations in the cervical cancer screening guidelines are based on strong 
evidence from randomized controlled trials comparing cytology alone to HPV co-
testing(9, 10) , providers faced with choosing between these options are calling for more 
direct “real-world” evidence of the harms and benefits of alternative screening strategies 
(17, 18).  To meet this demand, it is critical to first estimate the proportion of screening 
by each strategy and eventually the harms and benefits which result from them in actual 
practice.  We have been tracking the uptake of co-testing with the Johns Hopkins 
Hospital Pathology Data Systems since 2001.  Our prior analysis showed a rapid increase 
in co-test frequencies in women 30 years and older in 2009, reaching a plateau at 
approximately 40% by mid-2010.  The current analysis, which extends to May 2013, 
demonstrates a second wave of co-test increase beginning in 2012, to a mid-year peak of 
78% in 2013.  Here, we expand upon these analyses and examined correlates of co-test 
use by key demographic and clinic characteristics.  In time periods with less than 25% 
co-testing, a significantly higher frequency of co-testing was observed in women of black 
race and women with non-private medical insurance.  This difference by race and 
insurance type clustered within clinics, and demographic differences between clinics with 
higher versus lower co-test frequency appear to be a potential explanation for these 
differences.  Those clinic level differences attenuated significantly over time, suggesting 
that clinics with underserved minority and government-insured populations were the 
earliest adopters of co-testing.   
 
The overall increasing trend in co-testing frequency, however, masks substantial 
heterogeneity in practices between clinics within this single system.  Even in 2013, when 
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on average 78% of all tests included a co-test, some clinics still had rates below 10%.  
Furthermore, rates of co-testing by clinic did not increase universally.  While the majority 
of the clinics showed trends of increased co-testing, 4 of the 24 clinics with data in all 
three time periods did not.  These clinics only performed a small number of screening 
tests, however, and so we are uncertain of the significance of the observed decline in co-
testing over time.  Nonetheless, the stark contrast in co-test rates among clinics in this 
hospital system strongly illustrates the importance of clinic-wide policies in driving 
routine clinical practice.  Over the three time periods examined, the proportion of clinics 
that co-tested over 75% of patients increased from under 10% to almost 50%, while the 
proportion of clinics co-testing <25% of patients decreased from over 60% to about 20%.  
This finding is promising as providing a potentially impactful method to change medical 
practice on a larger scale than targeting individual patients or providers.  Like those of 
Tatsas et al., our results support the effectiveness of a top-down approach to making a 
policy change for the entire clinic, such that in the clinic where a decision to implement 
co-testing was decidedly put in place, rates appeared to quickly increase to almost 
complete compliance (10).   
 
Understanding the uptake of new technologies and changes to screening 
recommendations into routine clinical practice is an important step in streamlining 
implementation for future changes and ensuring that preventive healthcare is delivered as 
appropriately and effectively as possible.  Although we lacked a clear indication of which 
screening tests were ordered, by restricting our analysis to normal Pap results, we ensured 
that all HPV tests included would have been ordered as a co-test and not as a reflex test.  
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Furthermore, by defining a screening test as at least 300 days from a prior test, we aimed 
to eliminate most follow-up visits of a prior abnormal result, and could therefore more 
clearly look at co-test use in routine screening.  Importantly, this study utilized clinical 
practice data from a large medical system that includes a diversity of clinics and patients, 
providing direct evidence about how screening is occurring in a real world setting, not 
relying on self-report or vignette data as is frequently the case (10, 19-25).   
 
Our results suggest that while co-test prevalence has increased significantly over the last 
several years, these decisions appear to cluster at the practice-level not the system-level, 
and so tremendous variability exists on a clinic-by-clinic basis.  While this analysis is an 
important first step in assessing adoption of screening technologies, it only focused on 
those patients for whom co-testing is recommended—those aged 30-65 years.  However, 
studies have shown inappropriate use of screening and HPV tests in woman younger than 
30, women older than 65, and women with hysterectomies (8, 10, 19-21, 25, 26).  
Furthermore, the addition of HPV testing is only part of the screening recommendation, 
meant to go alongside a corresponding reduction in screening frequency because of the 
greater negative predictive value of using both tests.  As co-testing has now become the 
norm in many clinics, an important next step will be to explore whether screening 
intervals are simultaneously being extended, since increases in co-testing frequency 
without corresponding interval lengthening may result in increasing, rather than 











• Total PDS Records Obtained 
306,588 
• Restrict to females- drop males, unknown sex (n=164) 
306,540 
• Restrict to samples collected after Jan. 1, 2001 (n=18) 
306,464 
• Remove duplicate samples (n=76) 
304,771 
• Exclude if no Pap smear result (n=1693) 
271,345 
• Restrict to verified screening clinics (n=33426) 
166,064 
• Restrict to women of screening age who are co-test eligible (ages30-65) 
(n=105281) 
112,721 
• Restrict to time period where co-test uptake >5% (after 2005) (n=53343) 
98,809 
• Restrict to known insurance types (n=13915) 
57627 
• Restrict to assumed screening visits (>300 days after prior screen) 
(n=41182) 
55,575 
• Restrict to Pap negative results (n=2053) 
55,575 
• Final sample size 
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Age                     
 
30-39 16527 29.74 6458 39.08 5459 15.19 7654 45.96 3414 61.83 
 
40-49 15831 28.49 6045 38.18 5728 14.8 7295 46.91 2808 63.21 
 
50-59 15302 27.53 4711 30.79 6015 10.36 6821 38.09 2466 60.42 
 
60-65 7915 14.24 2031 25.66 3327 8.69 3458 31.93 1130 56.46 
Race                   
 
White 28324 50.97 7442 26.27 11638 7.61 12417 33.11 4269 57.27 
 
Black 20063 36.1 9461 47.16 6855 22.7 9143 56.52 4065 67.33 
 
Other 71888 12.93 2342 32.58 2036 7.22 3668 37.16 1484 56.06 
Insurance                     
 
Private 38644 69.53 12241 31.68 14747 9.32 16955 38.61 6942 62.24 
 
Medicare 4334 7.8 1219 28.13 2253 13.05 1581 39.78 500 59.2 
 
Medicaid 7128 12.83 3783 53.07 1863 32.27 3509 57.74 1756 62.64 
 
Tricare (Military) 5469 9.84 2002 36.61 1666 15.85 3183 45.27 620 47.9 
Insurance by Race                     
 
Private- White 21928 39.46 5576 25.43 9021 6.34 9384 31.02 3523 59.41 
 
Private- Black 11706 21.06 5027 42.94 4193 17.2 5194 52.81 2319 67.4 
 
Private- Other 5010 9.01 1638 32.69 1533 5.28 2377 37.53 1100 60.45 
 
Medicare- White 2308 4.15 379 16.42 1343 6.33 764 24.87 201 51.74 
 
Medicare- Black 1825 3.28 795 43.56 818 25.06 734 56.4 273 64.47 




Medicare- Other 201 0.36 45 22.39 92 4.35 83 30.12 26 61.54 
 
Medicaid- White 930 1.67 318 34.19 247 15.38 473 39.75 210 43.81 
 
Medicaid- Black 5651 10.17 3318 58.72 1525 39.8 2736 64.22 1390 68.63 
 
Medicaid- Other 547 0.98 147 26.87 91 13.19 300 27 156 34.62 
 
Tricare- White 3158 5.68 1169 37.02 1027 18.6 1796 45.77 335 46.57 
 
Tricare- Black 881 1.59 321 36.44 319 7.21 479 53.03 83 53.01 
  Tricare- Other 1430 2.57 512 35.8 320 15.62 908 40.2 202 48.02 
            *2013 includes visits through May 28, 2013 





























































    2006-2008 2009-2011 2012-2013 
    aPR1 (95% CI) aPR2 (95% CI) aPR1 (95% CI) aPR2 (95% CI) aPR1 (95% CI) aPR2 (95% CI) 
Age             
 
30-39 1 1 1 1 1 1 
 
40-49 1.05 (0.97-1.14) 1.04 (0.97-1.10) 1.04 (1.01-1.08) 1.02 (0.99-1.04) 1.03 (0.99-1.07) 0.99 (0.96-1.03) 
 
50-59 0.88 (0.80-0.97) 1.01 (0.95-1.09) 0.92 (0.88-0.95) 1.01 (0.98-1.03) 0.99 (0.95-1.04) 0.98 (0.94-1.03) 
 
60-65 0.72 (0.63-0.84) 1.03 (0.94-1.14) 0.83 (0.78-0.88) 1.00 (0.95-1.04) 0.94 (0.89-1.00) 0.96 (0.89-1.04) 
Insurance by Race             
 
Private- White 1 1 1 1 1 1 
 
Private- Black 1.23 (0.96-1.56) 1.18 (0.76-1.81) 0.87 (0.77-1.00) 0.94 (0.88-1.01) 0.89 (0.78-1.02) 1.03 (0.93-1.14) 
 
Private- Other 2.34 (1.73-3.17) 1.00 (0.86-1.17) 1.24 (1.10-1.39) 1.05 (0.97-1.15) 0.73 (0.63-0.85) 1.00 (0.93-1.08) 
 
Medicare- White 3.02 (2.60-3.51) 1.09 (0.99-1.19) 1.46 (1.38-1.55) 1.01 (0.97-1.06) 0.78 (0.70-0.88) 0.77 (0.59-1.00) 
 
Medicare- Black 2.62 (3.60-2.90) 0.91 (0.82-1.01) 1.65 (1.58-1.72) 1.06 (1.02-1.11) 1.13 (1.08-1.17) 1.10 (1.06-1.14) 
 
Medicare- Other 4.31 (3.71-5.00) 0.89 (0.79-1.00) 1.84 (1.72-1.98) 1.07 (1.00-1.15) 1.09 (0.99-1.19) 1.12 (1.04-1.22) 
 
Medicaid- White 5.94 (5.36-6.58) 0.92 (0.83-1.01) 1.98 (1.89-2.07) 1.11 (1.05-1.18) 1.14 (1.09-1.20) 1.13 (1.07-1.20) 
 
Medicaid- Black 1.15 (0.77-1.72) 0.79 (0.54-1.15) 1.67 (1.53-1.83) 0.99 (0.93-1.05) 0.89 (0.72-1.09) 0.91 (0.69-1.17) 
 
Medicaid- Other 0.81 (0.64-1.01) 0.89 (0.75-1.06) 1.17 (1.10-1.25) 1.00 (0.96-1.04) 1.01 (0.96-1.07) 1.05 (1.00-1.09) 
 
Tricare- White 0.82 (0.31-2.15) 0.65 (0.29-1.44) 1.05 (0.76-1.46) 0.99 (0.81-1.21) 1.05 (0.77-1.42) 1.16 (0.97-1.38) 
 
Tricare- Black 1.96 (1.15-3.45) 1.89 (1.07-3.35) 0.83 (0.69-1.00) 1.16 (1.02-1.32) 0.58 (0.47-0.72) 1.04 (0.90-1.19) 
  Tricare- Other 2.40 (1.84-3.14) 1.13 (0.91-1.38) 1.27 (1.16-1.38) 1.01 (0.96-1.07) 0.80 (0.69-0.93) 0.90 (0.81-1.00) 
*aPR1 includes age, race insurance adjustment 
  aPR2 – also includes clinic level adjustment  
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Chapter 3: Cervical cancer screening intervals 
following cytology and Pap/HPV co-testing in 
women over age 30 years: results from 





Objective:  Cervical cancer screening guidelines have been revised several times over the 
last decade, and now emphasize evidence-based medicine, resulting in recommendations 
for less frequent screening for both cytology alone and Pap/HPV co-testing.  Following 
these changes, few studies have reported the time to next screening test following a 
normal result over time. Here we estimate the length of time from a baseline screening 
test with normal results conducted between 2006 – 2010 to the next screening test.  In 
addition, we compare the interval between screens following a normal baseline test by 
age, race, and insurance to evaluate the predictors of use of extended screening intervals 
in clinical practice over time.  
 
Methods: This analysis included 31,701 Pap and HPV records from 18,048 women 
screened through from the Johns Hopkins Hospital (JHH) Pathology Data System (PDS) 
between 2006 and 2010. Median time to next visit along with corresponding 95% 
confidence intervals for were calculated by cytology alone vs co-test, year of screening, 
age, race, and insurance.  Hazard ratios and 95% confidence intervals for time to next 
screening test by cytology alone and co-testing were estimated using Cox proportional 
hazards models.  To account for the clustering of observations these same models were 
run with the addition of a random effects term for clinic.   
 
Results: Little change was seen over time in screening interval following cytology 
screening alone—the median time to next screening test remained between 1.4 and 1.5 
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years from 2006-2010.  However, we found an increase in the median time to next 
screening visit following a normal co-test result, with intervals increasing from about 1.5 
years in 2006/2007 when broader co-test uptake began to just over 2.5 years in 2010 
when 45% of screens included an HPV test.  These changes were not uniform as several 
differences in the median times to next screen were found among some of the age, race, 
and insurance subgroups.   
 
Conclusion:  No increases were seen in time to next screening test following a normal 
Pap smear, remaining at half the length of the recommended interval.  Following a co-
test, there was a steady increase in screening interval length over time, approaching 3 
years, which was the recommendation since at least 2003.  However, more time will be 
needed before we will be able to assess whether the most recent recommendation of 5-
year intervals after a dual negative co-test issued in 2012 is being followed.  Additionally, 
reasons for the differences we found by age, race and insurance, must be understood and 
corrected rapidly to prevent a widening of the disparities already seen in cervical cancer 








Routine Pap smear screening programs in the United States have reduced rates of cervical 
cancer by over 50% in the last 30 years due to the high proportion (>80%) of women 
screened (1, 2).  Recently, professional medical and public health organizations have 
begun to undertake evidence-based reviews of cancer screening guidelines, evaluating the 
harms relative to the benefits for each strategy.   These reviews led to revised guidelines 
for several cancers, often recommending less screening compared with previous 
guidelines.  In the past, there had been a lack of uniformity in the cervical cancer 
screening guidelines issued by different professional organizations.  However, in 2012, 
the US Preventive Service Task Force (USPTF), American Cancer Association (ACS), 
American Society for Colposcopy and Cervical Cytology (ASCCP), and American 
Society for Clinical Pathology (ASCP) issued updated consensus guidelines for cervical 
cancer screening.  These guidelines reemphasized the need for less frequent screening 
after a normal result, recommending screening either once every 3 years for cytology 
alone or once every five years after Pap/HPV co-testing (3, 4).  In their joint guidelines, 
the ACS, ASCCP, and ASCP specifically recommend against routine annual screening 
(3).  
 
As screening recommendations have evolved several times over the last decade, it is not 
immediately clear what guidelines are currently being followed (3, 5). There is no 
mandate for providers to adhere to evidence-based guidelines, and there is ample 
evidence to suggest a lack of adherence to the published guidelines.  Both focus groups 
and nationally representative surveys of physicians have shown that doctors frequently 
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recommend cervical cancer screening more often than indicated by the guidelines (6-8). 
Most of the previous studies about physician knowledge and adherence to guidelines 
have been based on self-report or response to vignettes and not on actual clinical practice 
(6-12).   
 
Two recent studies of a large academic medical center showed slow uptake of new 
screening practices, and within this single institution, rates of co-testing varied greatly by 
clinic (Chapter 2, 13, 14).  Similar trends were seen in data from other reference 
laboratories and academic primary care settings (15, 16), with one study showing that 
66% of women who were eligible for extended screening intervals had unnecessary 
screening tests performed between 2008 and 2009 (17).  However, few studies have 
reported the time to next screening test following a normal result over time.  In this study, 
we estimate the length of time from a normal baseline screening test conducted between 
2006 – 2010 until the next screen (screening interval).  We also compare the screening 
interval by age, race, and insurance in order to evaluate the predictors of adherence to 




Data source and data collection 
 
This analysis used data obtained from the Johns Hopkins Hospital (JHH) Pathology Data 
System (PDS), and included all Pap smear and HPV tests processed by the Pathology 
Department.  PDS is an in-house clinical database routinely used by the Pathology 
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Department to record and store test results.  It contains the results from any sample 
processed by the Hopkins Pathology Department, which receives samples from over 200 
clinics in and around the Baltimore area.  Records were obtained through a data use 
agreement with Johns Hopkins Hospital Systems, and a limited dataset was created to 
replace medical record numbers with a unique patient identifier.  The dataset included a 
patient identifier, patient age, race, zip code, insurance type, date of sample collection, 
date of test, test result, diagnosis, ordering physician and clinic where the patient was 
seen. All study procedures were approved by the Johns Hopkins Bloomberg School of 
Public Health Institutional Review Board.   
 
Pap smear and HPV test results were extracted from the free text diagnosis variable by 
searching for expressions or strings of words.  For this analysis, all Pap smear results 
were coded as normal (or no intraepithelial lesion or malignancy, NILM), atypical 
squamous cells of undetermined significance (ASCUS), low-grade squamous 
intraepithelial lesion (LSIL), atypical squamous cells- cannot rule out high grade lesion 
(ASC-H), high-grade squamous intraepithelial lesion (HSIL), carcinoma (cancer), or 
atypical glandular cells (AGUS) based on the most severe diagnosis in the text field. 
HPV testing was performed using the Digene hc2 test according to manufacturer’s 
instructions (Qiagen, Gaithersburg, MD) and results coded as negative (relative light unit 






We received all Pap smear and HPV test results in PDS processed between January 1, 
2001 and May 28, 2013, which was a total of 306,722 records, and then applied several 
restrictions to the data (Figure 3.1).  In brief, for the initial data cleaning step, we 
eliminated records with male or unknown sex, samples collected prior to January 1, 2001, 
duplicate records, and records without a Pap smear result.  We then restricted our dataset 
to include only samples collected from clinics likely to be performing routine screening 
(i.e., excluding specialty locations such as colposcopy and HIV clinics).  We performed 
our analysis only among women of routine screening age who were eligible for HPV co-
testing (ages 30-65), between January 1, 2006 when co-test prevalence first begins to 
increase and May 1, 2010 to allow for at least three years of follow-up.  This resulted in a 
final sample size of 31,701 records from 18,048 women.   
 
Insurance was characterized by type of provider: private (including HMOs, PPOs, Blue 
Cross), Medicare, Medicaid, and Tricare (military), and any records without an insurance 
code or with an insurance code that could not be verified were excluded.  To eliminate 
any HPV testing as a follow-up to a prior abnormal result and not as part of routine 
screening, we restricted our analyses to tests performed at least 300 days after a prior 
screen.  This restriction necessarily meant that only women with at least 2 records were 
included in this analysis.  Additionally, because there was no consistent code to indicate 
whether a co-test was ordered, we restricted the analysis to normal Pap results where 
there would be no other indication for HPV testing other than as a co-test.  Thus, co-tests 
were defined as any visit with a negative Pap smear that included an HPV test, and 92.6% 




Median times to next routine screening visit, along with corresponding 95% confidence 
intervals were calculated and graphed by cytology alone vs co-test, year of screening, 
age, race, and insurance.  Hazard ratios and 95% confidence intervals for time to next 
screening test for cytology alone and co-testing were estimated using Cox proportional 
hazards models.  To account for the clustering of observations within clinics, these 
models were also run with the addition of a random effect term for clinic.  All analyses 






The women included in this analysis had a median age of 48 years (interquartile range 
(IQR): 39-56).  Overall, this group was 55% white, 34% black, and 11% other races.  
Seventy percent had private insurance, 10% had Medicare, 10% Medicaid, and 10% had 
Tricare (military) insurance. 
 
Temporal changes in screening intervals 
 
Little change was seen over time in screening intervals following cytology screening 
alone—the median time to next screening test remained between 1.4 and 1.5 years from 
2006-2010 (Figure 3.2).  During this time, the proportion of screening tests that were co-
tests increased from 10% in 2006 to almost 50% by 2010.  We observed an increase in 
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the time to next screening test concomitant with temporal increases in co-test usage.  
Screening intervals following dual negative co-tests increased from around 1.5 years in 
2006 to 2.5 years in 2010 (Figure 3.2).   
 
Age-specific screening intervals 
 
Overall, only small differences (<3 months) were seen between age groups following 
cytology alone (Figure 3.3a).  Additionally, little change was seen in intervals across all 
age groups over time following a negative Pap smear, with medians staying between 1.2 
and 1.7 years throughout this time period.  Following cytology alone, the longest interval 
was seen among the oldest women, but only reached 1.6 years in 2010, only half as long 
as the currently recommended interval.  On the other hand, increases in median intervals 
were seen among all age groups receiving co-tests between 2006 and 2010, increasing 
from just under 1.5 years to 2.5 years for the youngest women and larger increases from 
1.75 years to 3.2 years for the oldest women (Figure 3.3b).  Younger women (age 30-39) 
had consistently shorter median intervals than older women following a dual negative co-
test, with this difference reaching a whole year at some points.   All ages saw an increase 
in intervals to at least every 2 years after co-testing, with the oldest women actually 
meeting at least a 3-year interval.  
 
Race and insurance-specific screening intervals 
 
Here we focused only on the differences between black and white race as the other race 
category was small and too heterogeneous to draw meaningful conclusions 
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(Supplementary Table S3.1). White women returned slightly sooner than black women 
following cytology alone (Figure 3.4a), with medians remaining generally remaining 
under 1.5 years for both races.  Conversely, following a co-test, black women returned 
sooner than white women (Figure 3.4b), with white women seeing a larger increase over 
this time period with intervals reaching almost 3 years (2.84, 95% CI: 2.66-3.02), while 
black women saw a much smaller increase, only reaching 2 years by 2009 (2.03, 95% CI: 
1.88-2.18).   
 
Differences were also seen by insurance type, such that women on Medicaid had the 
longest interval following cytology alone, but the shortest following a co-test (Figure 3.5a 
and 3.5b).  Among women screened by cytology alone, no change in interval was seen 
for private insurance (average of 1.4 years) or Medicaid (average of 1.8 years).  However, 
increases following negative cytology alone were seen for both Tricare and Medicare, 
each changing from 1.4 years in 2006 to about 2 years in 2010 (Figure 3.5a).  Unlike the 
cytology results, little change was seen among co-tested patients for Medicaid intervals 
(remaining just under 2 years- 1.84, 95% CI: 1.52-2.16), while private insurance and 
Tricare intervals increased to 3 years each.  Medicare intervals also increased to 3 years 
through 2009, but showed some decline in 2010 (Figure 3.5b).   
 
We also examined race and insurance as a combined variable of mutually exclusive 
categories. When median times to next screen are compared by race within each 
insurance type, several patterns emerge.  Women with private insurance have almost 
identical median screening intervals following cytology in 2010--1.25 years for white 
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women (95% CI: 1.17-1.33) and 1.32 years (95% CI: 1.21-1.43) for black women, but 
after co-testing black women return almost a year earlier than white women (Figure 
3.6a).  Among women with Medicare, black women initially had a longer median time 
for cytology but a shorter time for co-testing, though these differences attenuate with time 
so that in 2010, the median interval was 2 years for both races and screening 
methodologies (Figure 3.6b).  There was not enough data to estimate median intervals for 
white women being co-tested on Medicaid, but for all other women, the median 
fluctuates between 1.5 and 2 years with no real trend over time for both cytology and co-
testing (Figure 3.6c).  On the other hand, trends for median time differed by screening 
method, but not race, for all women with Tricare.  Intervals increased from 1.2 years to 3 
years between 2006 and 2010 after co-testing but only increased slightly in that time 
period for cytology (Figure 3.6d).   
 
Hazard Ratios for time to next screening visit 
 
To estimate the hazard ratios of age and race/insurance groups for time to next screen, we 
used data from the most recent time period (2009 to mid-2010) to capture the most 
current clinical scenario, and stratified by screening method (cytology alone or co-
testing) (Table 3.1).  Following cytology alone, older women had a shorter interval than 
younger women, and white women with private insurance had shorter screening intervals 
than all other race and insurance categories.  Conversely, following a dual-negative co-
test, older women had a longer interval than younger women, and white women with 




To account for the differences in clinic-level screening practices we have previously 
described, models were also run with a random effect term for clinic to account for 
clustering at that level.  With this additional adjustment, many results attenuated towards 
the null for both age and race/insurance categories and across both screening methods, 
though several significant differences remained.  Among those screened by cytology 
alone, both white and black women with Medicare had statistically significantly longer 
median intervals (HR: 0.87, 95% CI: 0.75-0.99; HR: 0.81, 95% CI: 0.66-0.99, 
respectively).  Differences also remained for co-testing after accounting for clinic-level 
differences—black women with private insurance (HR: 1.20, 95% CI: 1.05-1.37) and 
black women with Medicaid (HR: 1.30, 95% CI: 1.10-1.54) both had statistically 
significantly shorter screening intervals.  Older women also had much longer median 
intervals than younger women following co-testing (50-59 years HR: 0.85, 95% CI: 0.76-




We have previously shown differential uptake of co-testing on a clinic-level (Chapter 2, 
13, 18).  Here, we were able to build upon these earlier studies and show that along with 
an increase in the proportion of women being co-tested, there was also an increase in the 
median time before the next screening visit following a normal co-test result, but not 
following cytology alone.  Co-test intervals increased from about 1.5 years in 2006/2007 
when broader co-test uptake began to just over 2.5 years in 2010 when 45% of screens 
included an HPV test.  If the steady increase in screening interval length continues with 
time, the screening interval may reach three years, which was the recommendation since 
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at least 2003.  However, more time will be needed before we will be able to tell whether 
the most recent 2012 recommendation of a 5 year interval after a dual negative co-test is 
being followed.  These guidelines also stated that annual Pap smears were unnecessary 
and specifically recommended against them.  Instead, the guidelines emphasized that if 
screening was done by cytology alone, return screening should be every three years.  In 
this setting, we saw very little evidence of a lengthening interval among who were 
screened by cytology alone over the last several years in this population, remaining 
steadily around 1.5 years, suggesting a pattern of continued over-screening.   
 
Unlike the overall appearance of a lack of change in median cytology intervals over time, 
when stratified, several differences by race and insurance appear.  When comparing black 
and white women, the trends for each race are the same, though black women have a 
consistently longer interval of about 2-3 months.  This difference between black and 
white women becomes more striking with co-testing, though in the opposite direction—
black women are re-screened almost a year sooner than white women despite having the 
same test result.  Reasons for these differences in co-test screening intervals by race 
should be explored, as overuse of co-testing can actually increase the harms of screening, 
since the likelihood of false positives results and their sequelae increases with more 
frequent testing.   
 
Within an insurance type, the large difference in time to next screening by race following 
a co-test remained among women with private insurance, but essentially disappeared in 
the most recent years for women with government provided health insurance (Medicare, 
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Medicaid, Tricare). It is not very surprising to see more uniformity amongst the 
government-insured recipients, as those are run by a single body with a single set of 
policies and reimbursement patterns, while there is more heterogeneity among the 
different private insurers.  Pap screening intervals remained shortest for those with 
private insurance, possibly because private insurance continues to reimburse for annual 
Pap smears, while Medicare/Medicaid has moved to reimburse for Pap smears only once 
every two years and Tricare only once every three years.  This difference illustrates the 
power of financial considerations in guiding clinical practice.  Surprisingly, this pattern 
of longer intervals for non-private insurance did not hold for co-testing; instead, we found 
little evidence for extending intervals beyond two years for Medicare/Medicaid 
recipients, while both private insurance and Tricare intervals consistently increased 
through 2010.  While this again may be due in part to higher risk populations using 
Medicare and Medicaid, continued research is needed to better understand why we see 
these opposing trends across test methods within an insurance type.     
 
Some of these race and insurance differences appear to result from clinic-level 
differences in screening practice.  While almost all race/insurance categories differed 
significantly in hazard of returning for the next screening visit, many of those differences 
attenuated or completely disappeared once we accounted for the clustering of women 
within clinics and any clinic-level differences in practice.  It is interesting to note that the 
remaining differences are primarily among government-insured women.  Whether this is 
due to truly different risk histories or simply due to practice-level differences remains to 
be seen.  Further investigation into how screening policy decisions are made and 
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implemented at a clinic level could provide important implementation experience for 
clinics wishing to standardize their practice.   
 
Current screening guidelines state Pap smears should be performed no more often than 
once every three years, but the time to next screening visit following negative cytology 
continues to be at least a year shorter than recommended across all races and insurance 
types.  Often, screening is being performed at half the recommended interval, so those 
women are being screened twice as frequently as recommended.  Similarly, co-testing is 
only supposed to be done once every five years, or else any comparative benefit is lost, 
and yet all race and insurance sub-groups were screened at least once every three years.   
However, the 5-year interval is part of the newest recommendations and not enough time 
has elapsed yet to determine whether they are being adopted. Considering the slow 
uptake of co-testing initially, it is promising to the see the relatively rapid pace with 
which 3-year intervals are now being achieved.  The continued upward trajectories of 
those intervals is a promising trend that will need to be followed closely. Notably, black 
women are still only being screened approximately every 2 years after co-testing by both 
private insurance and Medicare/Medicaid, which is a year sooner than white women and 
is less than half the recommended interval.  This more frequent use of testing greatly 
increases the likelihood of false positives and negates the high negative predictive value 
that makes co-testing beneficial.  There is no immediately obvious explanation for this 
difference in intervals by race, as this comparison was among women with normal 




This analysis shows the initial adoption of newer screening algorithms with evidence of 
increasing time between tests, into routine clinical practice with co-testing, but not 
traditional Pap smear screening.  The recency of the newest guidelines precludes us from 
examining the long-term uptake until at least five years have passed, and so follow-up of 
these changes will be necessary.  Importantly, this study utilized clinical practice data 
from a large medical system that includes a diversity of clinics and patients, providing 
direct evidence about how screening is occurring in a real world setting.  However, with 
this clinical dataset, our analysis was limited to visits when patients are seen in an 
affiliated clinic and have a Pap smear and/or HPV test taken.  As a result, we lack a true 
population denominator, and do not know who is coming in and out of this cohort, and 
whether women are being screened elsewhere.  We also lack information on each 
women’s screening history prior to the data included, and so cannot rule out that some of 
the differences seen are due to true risk differences among the women where different 
follow-up algorithms may have been appropriate.  This is where comprehensive, 
population-based datasets created through the increasing use of electronic medical 
records and large screening registries such as the New Mexico Pap/HPV Registry (19) 
can supplement clinical data.  As more and more women are co-tested, the potential for 
increasing rather than decreasing costs to patients and the health care system grow.  
Reasons for the differences we found by age, race and insurance, must be understood and 
corrected rapidly to prevent a widening of the disparities already seen in cervical cancer 
screening, diagnosis, and treatment outcomes.     




Figure 3.1: Sample size flow chart 
306,722 
• Total PDS Records Obtained 
306,588 
• Restrict to females- drop males, unknown sex (n=164) 
306,540 
• Restrict to samples collected after Jan. 1, 2001 (n=18) 
306,464 
• Remove duplicate samples (n=76) 
304,771 
• Exclude if no Pap smear result (n=1693) 
271,345 
• Restrict to verified screening clinics (n=33426) 
166,064 
• Restrict to women of screening age who are co-test eligible (ages30-65) 
(n=105281) 
112,721 
• Restrict to time period where co-test uptake >5% (after 2005) (n=53343) 
98,809 
• Restrict to known insurance types (n=13915) 
57627 
• Restrict to assumed screening visits (>300 days after prior screen) 
(n=41182) 
55,575 
• Restrict to Pap negative results (n=2053) 
55,575 
• Final sample size 
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Figure 3.2: Time to next screen by year 
   





































Figure 3.3: Time to next screen by age 
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Figure 3.4: Time to next screen by race 
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*no median for white women in 2010 because <50% had returned for their next visit as 
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Figure 3.6: Median time to next screen by race and insurance 
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    Cytology alone Co-testing 
    aHR1 (95% CI) aHR2 (95% CI) aHR1 (95% CI) aHR2 (95% CI) 
Age  (in years)         
 
30-39 1 1 1 1 
 
40-49 1.19 (1.09-1.29) 1.12 (1.03-1.22) 0.99 (0.89-1.10) 0.97 (0.88-1.07) 
 
50-59 1.14 (1.06-1.24) 1.05 (0.96-1.14) 0.88 (0.79-0.99) 0.85 (0.76-0.96) 
 
60-65 1.09 (0.99-1.21) 0.94 (0.85-1.05) 0.68 (0.58-0.80) 0.63 (0.53-0.74) 
Insurance Type by Race         
 
White Private 1 1 1 1 
 
White Medicare 0.82 (0.72-0.95) 0.87 (0.75-0.99) 1.02 (0.76-1.37) 1.01 (0.74-1.36) 
 
White Medicaid 0.77 (0.61-0.97) 0.94 (0.73-1.22) 0.88 (0.61-1.27) 0.90 (0.61-1.31) 
 
White Tricare 0.79 (0.71-0.88) 0.92 (0.80-1.05) 1.24 (1.06-1.45) 1.15 (0.98-1.37) 
 
Black Private 0.92 (0.85-0.99) 0.98 (0.90-1.06) 1.34 (1.20-1.49) 1.20 (1.05-1.37) 
 
Black Medicare 0.71 (0.58-0.86) 0.81 (0.66-0.99) 1.21 (0.99-1.48) 1.05 (0.84-1.31) 
 
Black Medicaid 0.80 (0.71-0.91) 0.95 (0.80-1.13) 1.50 (1.33-1.70) 1.30 (1.10-1.54) 
  Black Tricare 0.93 (0.76-1.14) 0.99 (0.80-1.23) 1.13 (0.86-1.48) 1.05 (0.80-1.39) 
 
*aHR1 includes age, race insurance adjustment 
aHR2 – also includes clinic level adjustment  
 







% of analytic 
population 
Asian 1,016 3.2 
Hispanic 362 1.14 
Indian 36 0.11 
Mixed 10 0.03 
Other 804 2.54 
Unknown 1227 3.87 
Missing 120 0.38 
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Objective: To explore attitudes towards new cervical cancer screening options and 
understand factors associated with those beliefs among women in routine gynecologic 
care.     
 
Methods: Interviewer-administered survey of 551 women aged 36-62 enrolled in the 
HPV in Perimenopause Study.  Poisson regression with robust error variance was used to 
estimate prevalence ratios and 95% confidence intervals to compare women’s preferences 
for cervical cancer screening methods and frequency. 
 
Results: A majority of women (55.6%, 95%CI: 51.4-59.8%) were aware that screening 
recommendations had changed, yet 77.9% (95%CI: 74.3-81.3%) still believed women 
should be screened annually.  If recommended by their doctor, 68.4% (95% CI: 64.4-
72.2%) were willing to extend screening to every three years, but only 25.4% (95%CI: 
21.9-29.2%) would extend screening to five years.  Most women (60.7%, 95%CI: 56.5-
64.7%) expressed a strong preference for Pap testing, and 41.4%  (95%CI: 37.4-45.6%) 
expressed at least moderate concern over having an HPV test without a Pap test.  A desire 
for more frequent care, higher degree of worry and perceived risk, and abnormal 
screening history were all associated with reduced willingness to accept HPV testing and 
longer screening intervals.   
 
Conclusion: A majority of routinely screened women indicated a willingness to adopt a 
cervical cancer screening strategy of cytology alone or Pap-HPV co-testing every 3 years 
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if recommended by their physician.  However, they remain concerned about HPV testing 
and extension of screening intervals to once every 5 years.  Our results suggest continued 
reticence to accepting newer HPV-based screening algorithms among routinely screened 






In 2012, the US Preventive Services Task Force, American Cancer Society, American 
Society for Colposcopy and Cervical Cytology, and American Society for Clinical 
Pathology updated their joint guidelines for cervical cancer screening, specifically 
recommending against annual screening using any strategy (1). Cytology alone at 3-year 
intervals and HPV co-testing with cytology at 5-year intervals were both considered 
acceptable strategies for women aged 30-65 years.  While primary screening with HPV 
testing was not in the 2012 guidelines, in April 2014 the US Food and Drug 
Administration approved the Roche Cobas® HPV test for primary screening, and interim 
guidelines for a primary HPV screening strategy are anticipated. 
 
HPV co-testing with a 3-year screening interval has been an acceptable option since 
2003, yet uptake of co-testing in clinical practice has been slow (2, 3).  Studies have 
shown that despite these guidelines, physicians continue to screen more frequently than 
recommended (4-9), and surveys have indicated that patient anxiety and expectation of 
annual screening influence a provider’s screening recommendation (10, 11).  Because 
recommendations strive to achieve a balance between benefits and both physical and 
psychological harms of screening, it is important to assess patient preferences and 
attitudes towards each alternative cervical cancer screening strategy. 
 
We assessed the attitudes towards HPV testing strategies and patient-specific factors 
associated with willingness to lengthen screening intervals to 3- or 5-years in a cohort of 
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routinely screened women ages 36-62 years participating in a natural history study of 




A survey to assess knowledge of the cervical cancer screening guideline changes, current 
screening practices, preferred screening method and frequency, willingness to extend the 
screening interval, and perceived risk of HPV and cervical cancer was offered to all 
women completing the HPV in Perimenopause Study final study visit.  Five-hundred 
sixty-six of 885 women enrolled into the HPV in Perimenopause Study (64.0%) 
completed the final study visit, and 551/566 (97.3%) completed the screening-focused 
survey.  Women who completed the full two years of follow-up did not differ 
significantly on any of the demographic or baseline risk factor variables from the total 
885 women enrolled (Table 4.1).   
 
Details of the HPV in Perimenopause Study have been reported elsewhere (12, 13).  In 
brief, women receiving routine gynecological care were recruited to participate from 
Johns Hopkins Hospital affiliated outpatient OB/GYN clinics in Baltimore, MD from 
March, 2008 to March, 2011.  Women were eligible to participate in the study if they 
were between 35 and 60 years, had an intact cervix, and were willing to provide informed 
consent. Women were not eligible for enrollment into the study if they were pregnant, 





During this 2-year prospective natural history study of HPV infection in the menopausal 
transition, consenting women provided information on socio-demographic characteristics, 
lifetime sexual history and current sexual behavior, cervical cancer screening history, 
menstrual and reproductive histories, medication, and alcohol and tobacco use via a 
telephone-administered questionnaire.  All women underwent a speculum-assisted pelvic 
examination, with swab and secretion samples collected for research purposes.  A HIPAA 
waiver was signed allowing the study to abstract all cervical cytology and HPV test 
results obtained clinically during their study participation from their medical records. 
Several patient-specific factors evaluated in this study (including screening history, 
sexual behavior, and clinical Pap/HPV results) were derived from these data sources.  
The questions asked to participants in the screening study are included in the appendix 
(Supplementary Table S4.1). All study procedures were approved by the Johns Hopkins 
Bloomberg School of Public Health Institutional Review Board.   
 
Descriptive statistics including frequencies and proportions and their corresponding 
confidence intervals were estimated to summarize survey responses.  Poisson regression 
with robust error variance was used to estimate unadjusted prevalence ratios (PRs) and 
corresponding 95% confidence intervals (95% CI) comparing women willing to be 
screened every three years (by Pap only or by Pap/HPV co-testing) to women unwilling 
to extend screening intervals beyond one year.  Women willing to extend screening to 
every five years following a dual negative co-test were also compared to women only 
willing to extend to three years.  Women preferring Pap testing only were compared to 
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women preferring HPV testing only or who didn’t express a preference.  All analyses 




The women in this analysis were between 36 and 62 years of age with a median age of 50 
(IQR: 44-55) at the time of the screening survey administration.  The majority of women 
were white (76.2%), married (64.7%) and currently non-smokers (91.8%) (Table 4.1).  
Many women (60.9%) reported having five or more lifetime sex partners and at the time 
of the final visit, 70.0% reported sex with a steady partner, 25.5% were not sexually 
active, and 4.6% reported having a new sex partner in the prior six months.  Most 
participants had some education beyond high school (85.0%), with 64.6% completing 
college and/or a post-graduate degree and 80.1% reported household incomes of $40,000 
or higher.   Consistent with our planned recruitment from women attending routine 
OB/GYN visits, all women reported having had a prior Pap smear, 47.2% reported 
having an abnormal Pap smear prior to study enrollment, and 99% reported a having a 
Pap smear within the past three years.  In addition to OB/GYN care, participants were 
actively engaged in other medical care—less than 1% of women reported that their 
OB/GYN was their primary care physician and 97.6% had a check-up or physical in the 
past 5 years (Table 4.2).  Additionally, 92.2% of women reported cholesterol tests, 75.1% 
reported diabetes screens, and 88.4% mammograms in the past 5 years.   
 
A majority of participants (55.6%, 95%CI: 51.4-59.8) were aware that current cervical 
cancer screening guidelines recommended against annual screening (Table 4.2).  
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However, when asked how often they thought women their age should have a Pap smear, 
3.8% (95%CI: 2.5-5.8) reported more than once a year, 74.1% (95%CI: 70.3-77.7) 
reported yearly, 13.4% (95%CI: 10.8-16.6) reported every other year, and 6.4% (95%CI: 
4.6-8.7) reported every three years or longer.  Despite a majority believing that screening 
should occur annually, over two-thirds of participants (68.4%, 95% CI: 64.4-72.2) were 
willing to extend their screening to once every three years by either Pap only or Pap-HPV 
co-testing following a normal result if a doctor recommended it; however, among those 
women willing to be screened every three years, only 39.5% (95%CI: 34.5-44.7), which 
was 25.2%, (95%CI: 21.8-29.0,) of women overall, were willing to extend screening to 5 
years.  Over two-thirds of participants (69.7%, 95%CI: 65.7-73.4) indicated that they 
would continue annual OB/GYN well-woman visits even if Pap screening was not 
performed.  This proportion remained unchanged when restricted to the women willing to 
be screened every three years or longer.  Primary reasons cited for continuing annual 
visits included a desire for routine check-up/ physical exam, other gynecologic concerns, 
breast exams, to maintain relationships with their doctor, and reassurance that everything 
is okay. 
 
When asked about screening test preference, 60.7% (95%CI: 56.5-65.7) of women 
preferred Pap smears only, 31.5% (95%CI: 27,7-35.5) did not have a preference and were 
willing to be screened by either Pap or HPV testing, and only 7.8% (95%CI: 5.9-10.4) 
preferred HPV testing alone (Table 4.2).  Furthermore, 30.1% (95%CI: 26.4-34.1) of 
women reported they would experience moderate anxiety and 11.3% (95%CI: 8.9-14.3) 
reported severe anxiety if they were screened with an HPV test alone.  When asked which 
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test result they found more concerning, 26.6% (95%CI: 23.0-30.4) said an abnormal Pap 
result and 9.3% (95%CI: 7.1-12.0) reported an HPV positive result, with the majority 
reporting them to be equally concerning.  To understand factors associated with screening 
assay preference, univariate analyses compared women who preferred Pap testing alone 
to the women who didn’t have a preference or preferred HPV testing (Table 4.3).  
Women with a higher household income (PR: 0.56, 95% CI: 0.35-0.90), women recruited 
from the clinic that routinely co-tests (PR: 0.80, 95% CI: 0.69-0.93), women who were 
more concerned about an HPV positive test (PR: 0.45, 95% CI: 0.31-0.66) or equally 
concerned about an abnormal Pap/HPV result (PR: 0.73, 95% CI: 0.65-0.83), or thought 
they had a moderate or high risk of HPV (PR: 0.67, 95% CI: 0.49-0.92) were more likely 
to not have a test preference or to prefer HPV only compared with preferring Pap testing 
alone.  Women with moderate (PR: 1.54, 95% CI: 1.25-1.90) or severe (PR: 1.39, 95% 
CI: 1.07-1.80) concern about HPV only testing preferred Pap only testing compared with 
women with low/no concern about HPV only testing.   
 
In univariate analyses, we saw little to no difference in willingness to be screened every 
three years versus annually by age, race, marital status, education, and menopausal status 
(Table 4.4).  Women with household income below $40,000 were 30% more likely (PR: 
1.3, 95% CI: 1.1-1.5) to agree to extended screening intervals than women with higher 
income.   Women seen at clinic B (which instituted a clinic-wide co-test policy in 2009) 
were more likely to agree to extended intervals (PR: 1.2, 95% CI: 1.1-1.4) compared with 
women recruited from clinic A which did not have a consensus co-testing policy.  
Participants’ knowledge and attitudes towards cervical cancer screening, as well as self-
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reported screening history, were among the strongest predictors of whether a woman was 
willing to be screened every three years.  Both women who had last been screened longer 
than a year ago (PR: 1.3, 95% CI: 1.2-1.5) and women who didn’t expect to have their 
next Pap smear screening for at least one year (PR 1.4, 95% CI: 1.2-1.5 next screen 
within 2 years; PR 1.4, 95% CI: 1.1-1.7 next screen within 5 years) were 30-40% more 
likely to agree to a 3-year screening interval.  Women who believed Pap smears should 
be done every other year (PR: 1.3 95% CI: 1.2-1.5) or every 3-5 years (PR 1.5, 95% CI: 
1.4-1.7) were also significantly more likely to state they would accept extended screening 
intervals than those who thought screening should be yearly or more often.  Prior 
knowledge of the change in screening guideline was not associated with an increased 
willingness to follow the new guidelines.  Women with a history of an abnormal Pap 
smear in the last 5 years were at least 30% less likely to agree to extended intervals (PR: 
0.7, 95%CI: 0.5-0.9 extend to 3 years; PR: 0.5, 95% CI: 0.2-1.0 extend to 5 years).  
Women who reported a moderate to high perceived risk of developing cervical cancer in 
the future were 30% less willing to extend screening intervals to 3 years (PR: 0.7, 95% 
CI: 0.6-0.9), but no association was seen with perceived risk of HPV infection or genital 
warts.  Risk factors for HPV infection and cervical cancer such as lifetime number of sex 
partners, recent new sex partners, HPV serology status, and HPV DNA status were also 
not associated with a woman’s willingness to follow the 3-year screening 
recommendation.   
 
Only 39.5%  (95%CI: 34.5-44.7) of women willing to be screened every three years 
(25.2%, 95%CI: 21.8-29.0 of all women) were willing to be screened every 5 years 
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(Table 4.4).  Women with a BMI over 30 were 50% more likely to accept a 5-year 
interval (PR: 1.5, 95% CI: 1.1-2.0). Many of the same determinants of willingness to 
extend to 3-year intervals were associated with willingness to extend to 5-year intervals 
though these associations did not reach statistical significance in this smaller sample.  No 
significant associations were seen with risk factors of lifetime number of sex partners, 




Cervical cancer screening has evolved significantly in the past 10-15 years.  However, 
the preference of women regarding alternative screening strategies is an understudied 
aspect of changing screening guidelines.  In our survey of routinely screened women 36-
62 years, we found that almost half were aware that screening recommendations had 
changed, and the majority still believed women should be screened every year.  Despite 
this, two-thirds stated they would be willing to extend screening to every three years if 
their doctor recommended it, but only a quarter were willing to extend the interval to five 
years following a dual negative co-test, the preferred recommendation in the newest 
guidelines.  Women also expressed a clear preference for Pap testing over HPV testing, 
and many expressed concern over having an HPV test alone without a Pap test.  A desire 
for more frequent care, higher anxiety, and higher perceived risk were all associated with 
being less willing to accept alternatives to annual Pap smears.   
 
Resistance to less frequent screening has been reported previously (14-21), and this 
reticence appears to persist over time.  For example, the results from a nationally 
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representative survey of women in the US in 2005 were strikingly similar to our survey 
results collected almost a decade later (15).  Our results suggest a continued preference 
for cytology testing compared with HPV testing.  This observation is especially relevant 
in light of the recent FDA approval of one HPV test (Roche Cobas) for an indication of 
primary cervical cancer screening (22).  Future US guideline revisions are likely to 
consider recommendations for primary screening using HPV testing, especially given the 
transition to primary HPV screening by other large national screening programs such as 
those in Australia (23) and the United Kingdom (24).   
 
Interestingly, despite the preference for Pap over HPV testing, women in our study were 
more concerned about an abnormal Pap test compared to a positive HPV test.  Data from 
a large study of women routinely screened with an HPV co-test algorithm showed 35% of 
CIN3/AIS and 29% of total cancers were in women with HPV positive and cytology 
negative co-test results (25).  Taken together, these results suggest that educational 
interventions to communicate risks associated with alternative screening test results are 
needed in order for women to make understand alternative screening choices.     
 
Women with a lower household income were more likely to accept longer screening 
intervals, which may be related to the cost saving aspect of reducing unnecessary tests or 
other barriers such as difficulty scheduling time off work for preventative health care 
needs.  In addition, women with high levels of worry and/or high perceived risk, as well 
as women who indicated a preference for more care and contact with their provider were 
less likely to agree to extended screening intervals, as previously shown (14, 26).  These 
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women may represent a combination of those with historically high risk, who should be 
screened more frequently (27), as well as a subset of ‘worried well’ in whom frequent 
screening appears to be the result of a desire for continual reassurance.   
 
Surveys of physicians have indicated that concern about losing the well-woman annual 
clinical encounters as a result of less frequent screening was a common barrier to use of 
co-testing strategies, which are cost-effective only when performed at the recommended 
extended intervals (8, 28).  It is important to understand whether a lack of willingness to 
extend the cervical cancer screening interval reflects a concern among the patients about 
missing other opportunities for care.  We found that nearly 70% of women reported that 
they would continue annual well-women visits even if a Pap smear was not taken at each 
visit.  However, our questions did not explicitly ask about willingness to extend screening 
intervals in the context of continued annual gynecologic exams, and thus it is possible 
that acceptance would be higher if women are reassured that less frequent screening 
would not result in less frequent general gynecologic care.    
 
A unique strength of our analysis was the ability to nest responses into a larger and more 
comprehensive evaluation of the natural history of HPV infection.  For example, women 
in this study were primarily recruited from two GYN practices, which had distinctly 
different screening policies.  We observed that women recruited from the clinic with a 
practice-wide policy of routine co-testing in women over 30 since 2009 were slightly 
more likely to accept extended intervals than those being screened in the other clinics 
with less frequent use of co-testing.  However, having had one or more HPV tests or 
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being in the clinic with a policy of routine co-testing was not associated with a woman 
being more comfortable with HPV only testing, again highlighting a need for more 
patient education regarding the use and meaning of HPV testing.   
 
A limitation of this cohort is that it is not representative of the general population.  Our 
study participants are older, of higher socio-economic status, and are in routine screening. 
Despite this, we believe that the responses from this population are particularly relevant 
when the aim is to examine the attitudes towards changes in routine screening guidelines, 
since it is the well-screened women who would be most affected by extension of 
screening intervals.  Moving forward, it will be important to assess whether more diverse 
or representative populations also express similar attitudes towards screening strategies.  
We also acknowledge that screening involves a dialog between patient and provider, and 
we have only provided the patient perspectives.  Future studies incorporating both patient 
and provider perspectives will be essential for a complete evaluation of the dynamics of 
this shared decision-making.  In addition, many of the questions were phrased as 
screening intentions and future behaviors, and it is thus unclear whether these intentions 
will directly translate to practice.  All of the information collected in our questionnaire 
are self-reported and so are subject to inaccuracies in recall and reporting.  Despite these 
limitations, these data contribute to a significant gap in the evidence regarding patient 
perceptions of benefits and harms of screening, which have been historically 
underrepresented in cervical cancer screening guideline development. 
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Demographics           
Age (years)     
 35-39 95 17.2  162 18.3 
 40-44 112 20.3  187 21.1 
 45-49 143 26.0  223 25.2 
 50-54 120 21.8  181 20.5 
 55-60 81 14.7  132 14.9 
Race      
 White 420 76.2  653 73.8 
 Black 91 16.5  167 18.9 
 Other 40 7.3  65 7.3 
BMI 
     
 








Obese 270 30.5 
 
149 27.2 
Income ($)     
 <40,000 35 6.4  66 7.5 
 40-80,000 125 22.7  212 24.0 
 80-120,000 133 24.2  195 22.0 
 120,000+ 183 33.3  261 29.5 
 Unknown 74 13.5  150 16.9 
Clinic      
 Clinic A (no co-test policy) 293 53.3  449 50.7 
 Clinic B (co-test policy) 224 40.7  385 43.5 
 Clinic C (no co-test policy) 33 6.0  51 5.8 
Married      
 Never 84 15.3  164 18.6 
 Divorced/ Widowed/ 
Separated 
110 20.0  165 18.7 
 Married 356 64.7  555 62.8 
Education      
 High school or less 82 15.0  153 17.3 
 Some post high school 112 20.4  208 23.5 
 College graduate 171 31.2  257 29.0 
 Post graduate 183 33.4  267 30.2 
Smoking      
Table 4.1: Comparison of Total Enrollment Population 
with Women Completing Study 
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 Never 393 71.9  608 68.7 
 Former 109 19.9  176 19.9 
 Current 45 8.2  101 11.4 
Menopausal Status (BL)      
 Premenopausal 224 40.7  373 42.2 
 Perimenopausal 165 30.0  260 29.4 
 Postmenopausal 149 27.0  233 26.3 
 Not Classified 13 2.4  19 2.2 
Screening History           
Time Since Last Abnormal Pap (BL)    
 Never abnormal 291 52.8  465 52.5 
 0-5 years 62 11.3  114 12.9 
 6+ years 182 33.0  286 32.3 
 Unknown 16 2.9  20 2.3 
Ever Had Colposcopy (BL)     
 No 417 76.1  694 78.4 
 Yes 131 23.9  191 21.6 
Risk Factors           
Lifetime Number of Sex Partners at Enrollment    
 <5 214 39.1  335 38.0 
 5+ 333 60.9  547 62.0 
Recent Sex      
 No Sex 140 25.5  199 22.6 
 Yes, no new partner 385 70.0  655 74.5 
 Yes, new partners 25 4.6  25 2.8 
HPV Serology at BL      
 Negative 190 40.9  273 37.9 
 Positive 275 59.1  448 62.1 
Research HPV Testing (during study)    
 Always negative 448 81.3  735 83.1 
 Ever positive 103 18.7  150 16.9 
Clinical Pap Abnormality (during study)    
 No 507 93.2  811 93.1 
 Yes 37 6.8  60 6.9 
Clinical HPV Test (during study)     
 




Ever positive 26 4.8 
 
42 4.8 
  Not tested 201 36.9   354 40.6 
* p>.05 for all comparisons between visits (no significant differences) 
  Abbreviations: N= number, %= percent, BL=baseline, indicates data only 
collected at time of study enrollment, Recent Sex= within the last 6 months  
  Missing data: N=3 for smoking, education, ever had colposcopy; N=1 for recent 
sex; N=10 for Pap result during study; N=6 for clinical HPV test; N=86 for 
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serology (unable to get blood sample) 
    N % 95% CI 
How often should women have a Pap smear?   
 Yearly 408 74.1 70.3-77.7 
 Every other year 74 13.4 10.8-16.6 
 Every 3 or longer 35 6.4 4.6-8.7 
 
More than once a year 21 3.8 2.5-5.8 
Don't know 13 2.4 1.2-3.8 
Aware of the guideline change?   
 No 240 43.6 39.5-47.8 
 Yes 306 55.6 51.4-59.8 
 Don't Know 5 0.9 0.3-1.9 
Willing to have an annual without a Pap   
 No 132 24.1 20.7-27.9 
 Yes 382 69.7 65.7-73.4 
 Don't Know 34 6.2 4.5-8.6 
Screening Test preference    
 Pap Only 333 60.7 56.5-65.7 
 HPV Only 43 7.8 5.9-10.4 
 Either 173 31.5 27.7-35.5 
Which is more concerning   
 Abnormal Pap 146 26.6 23.0-30.4 
 HPV Positive 51 9.3 7.1-12.0 
 Equally concerning 353 64.2 60.1-68.1 
If HPV test only, how much concern about not having a Pap smear 
 None 120 21.9 18.6-25.6 
 Slight 201 36.7 32.7-40.8 
 Moderate 165 30.1 26.4-34.1 
 Severe 62 11.3 8.9-14.3 
Perceived Risk of Warts    
 None/Low 518 95.1 92.9-96.6 
 Moderate/High 27 5.0 3.4-7.1 
Perceived Risk of HPV    
 None/Low 492 89.6 86.8-91.9 
 Moderate/High 57 10.4 8.1-13.2 
Perceived Risk of Cervical Cancer   
Table 4.2: Knowledge, Attitudes, and Preferences 
towards Cervical Cancer Screening & Guidelines 
 
 106 
 None/Low 475 86.5 83.4-89.1 
 Moderate/High 74 13.5 10.9-16.6 
Willing to be screened every 3 years by either Pap only or co-testing 
 No 174 31.6 27.8-35.6 
 Yes 377 68.4 64.4-72.2 
If willing to be screened every 3 years, willing to extend to 5 years 
 No 213 60.5 55.3-65.5 
 Yes 139 39.5 34.5-44.7 
Have pap every 5 years if Pap & HPV tests normal  
 No 412 74.8 71.0-78.2 
 Yes 139 25.2 21.8-29.0 
Other Health Behaviors       
Primary care provider? 
   
 
Internist/ Family Practitioner 476 86.4 83.3-89.0 
 
Physician's Assistant 18 3.3 2.1-5.1 
 
Nurse Practitioner 14 2.5 1.5-4.3 
 
Gynecologist 5 0.9 0.4-2.2 
 
Other Medical Specialist 7 1.3 0.6-2.6 
 
Don't know/ can't remember 3 0.5 0.2-1.7 
 
No primary care provider 28 5.1 3.5-7.3 
In the last 5 years had a … 
  
 
General health check-up or physical 538 97.6 96.0-98.6 
 
Cholesterol test 508 92.2 89.6-94.2 
 
Diabetes screen or blood glucose 
test 417 75.7 71.9-79.1 
 
Dental Exam 527 95.6 93.6-97.1 
 
Clinical breast exam 534 96.9 95.1-98.1 
  Mammogram 487 88.4 85.4-90.8 
* Abbreviations: N=number, %=percent;  
Missing data: N=3 for annual w/o Pap, HPV only; N=2 test  




  N (%) PR CI 
Demographics       
Age    
 35-39 59 (62.1) 1  
 40-44 61 (54.5) 0.88 .70-1.11 
 45-49 85 (59.4) 0.96 .78-1.18 
 50-54 81 (68.1) 1.10 .90-1.34 
 55-60 47 (58.8) 0.95 .74-1.20 
Race    
 White 256 (61.0) 1  
 Black 53 (58.9) 0.97 .80-1.17 
 Other 24 (61.5) 1.01 .78-1.31 
BMI    
 Normal 140 (63.4) 1  
 Overweight 108 (61.4) 0.97 .83-1.13 
 Obese 84 (56.4) 0.89 .75-1.06 
Income ($)    
 <40,000 268 (60.9) 1  
 40,000+ 12 (34.3) 0.56 .35-.90 
 Unknown 53 (71.6) 1.16 1.0-1.38 
Clinic    
 Clinic A (no co-test policy) 195 (66.8) 1  
 Clinic B (co-test policy) 120 (53.6) 0.80 .69-.93 
 Clinic C (no co-test policy) 18 (54.6) 0.88 .59-1.13 
Married    
 Never 50 (59.5) 1  
 Divorced/ Widowed/ Separated 66 (60.0) 1.01 .80-1.27 
 Married 216 (61.0) 1.03 .84-1.25 
Education    
 High school or less 44 (53.7) 1  
 Some post high school 70 (62.5) 1.16 .91-1.49 
 College graduate 104 (60.8) 1.13 .90-1.43 
 Post graduate 114 (63.0) 1.17 .93-1.48 
Smoking    
 Never 241 (61.6) 1  
 Former 64 (58.7) 0.95 .80-1.14 
 Current 27 (58.7) 0.95 .74-1.23 
Table 4.3: Correlates of Preference of Pap Only Screening (compared 
to HPV only or either) 
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Menopausal Status    
 Premenopausal 134 (59.8) 1  
 Perimenopausal 103 (62.4) 1.04 .89-1.22 
 Postmenopausal 90 (61.2) 1.02 .87-1.21 
 Not classified 6 (46.2) 0.77 .42-1.40 
Screening History       
Time Since Last Abnormal Pap (BL)   
 No abnormal Pap ever 176 (60.7) 1  
 0-5 years 38 (61.3) 1.01 .81-1.26 
 6+ years 112 (61.9) 1.02 .88-1.18 
 Unknown 7 (43.8) 0.72 .41-1.27 
Ever Colposcopy (BL)    
 No 255 (61.3) 1  
 Yes 77 (59.2) 0.97 .82-1.14 
When was last Pap    
 Within last year 266 (61.9) 1  
 1-5 years ago 65 (56.5) 0.91 .77-1.09 
 Don't Know 1 (33.3) 0.54 .11-2.68 
Next Expected Pap    
 Within a year 273 (62.1) 1  
 Within 2 years 49 (61.3) 0.99 .82-1.19 
 Within 5 years 5 (33.3) 0.54 .26-1.10 
 Don't Know 6 (42.9) 0.69 .38-1.27 
Risk Factors       
Lifetime Number of Sex Partners (BL) 
 <5 128 (60.4) 1  
 5+ 204 (61.3) 1.01 .88-1.17 
Recent Sex*    
 No sex 84 (60.0) 1  
 Yes, no new partner 235 (61.4) 1.02 .87-1.20 
 Yes, new partners 14 (56.0) 0.93 .65-1.36 
HPV Serology at BL    
 Negative 120 (63.5) 1  
 Positive 162 (59.1) 0.93 .80-1.08 
Research HPV Status (during study)   
 Always negative 277 (62.0) 1  
 Ever positive 56 (54.9) 0.89 .73-1.07 
Clinical Pap Abnormality (during study)   
 No 311 (61.6) 1  
 Yes 19 (51.4) 0.83 .60-1.15 
Clinical HPV Testing (during study)   
 Negative 182 (57.6) 1  
 Positive 10 (38.46) 0.67 .41-1.10 
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 Not Tested 138 (68.7) 1.19 1.04-1.36 
Knowledge and Attitudes towards Cervical Cancer Screening & Guidelines 
How often should women have Pap smear?   
 Yearly 262 (64.5) 1  
 Every other year 40 (54.1) 0.84 .67-1.05 
 Every 3-5 years 16 (45.7) 0.71 .49-1.02 
 More than once a year 12 (57.1) 0.89 .61-1.29 
 Don't know 2 (16.7) 0.26 .07-.92 
Aware of the guideline change?   
 No 143 (59.6) 1  
 Yes 186 (61.2) 1.03 .89-1.18 
 Don't Know 3 (75.0) 1.26 .71-2.24 
Willing to have annual without Pap   
 No 78 (59.1) 1  
 Yes 231 (60.6) 1.03 .87-1.21 
 Don't Know 23 (67.7) 1.14 .87-1.50 
Which is more concerning    
 Abnormal Pap 114 (78.1) 1  
 HPV Positive 18 (35.3) 0.45 .31-.66 
 Equally concerning 201 (57.1) 0.73 .65-.83 
If HPV test only, how much concern about not having a Pap smear 
 None 57 (47.5) 1  
 Slight 114 (56.7) 1.19 .95-1.49 
 Moderate 120 (73.2) 1.54 1.25-1.90 
 Severe 41 (66.1) 1.39 1.07-1.80 
Perceived Risk of Warts    
 None/Low 316 (61.2) 1  
 Moderate/High 13 (48.2) 0.79 .53-1.17 
Perceived Risk of HPV    
 None/Low 307 (62.7) 1  
 Moderate/High 24 (42.1) 0.67 .49-.92 
Perceived Risk of Cervical Cancer   
 None/Low 290 (61.3) 1  
  Moderate/High 42 (56.8) 0.93 .75-1.14 




  Extend to 3 years only  Extend from 3 to 5 years 
  N (%) PR CI N (%) PR CI 
Demographics             
Age (years)          
 35-39 67 (70.5) 1  28 (43.1) 1  
 40-44 65 (58.0) 0.8 0.7-1.0 34 (54.0) 1.3 0.9-1.8 
 45-49 102 (71.3) 1.0 0.9-1.2 29 (31.2) 0.7 0.5-1.1 
 50-54 82 (68.3) 1.0 0.8-1.2 25 (33.8) 0.8 0.5-1.2 
 55-60 61 (75.3) 1.1 0.9-1.3 23 (40.4) 0.9 0.6-1.4 
Race        
 White 298 (80.0) 1  108 (38.9) 1  
 Black 55 (60.4) 0.9 0.7-1.0 20 (40.0) 1.0 0.7-1.5 
 Other 24 (60.0) 0.9 0.7-1.1 11 (45.8) 1.2 0.7-1.9 
BMI        
 Normal 152 (68.5) 1  49 (34.0) 1  
 Overweight 126 (71.2) 1.0 0.9-1.2 45 (38.8) 1.1 0.8-1.6 
 Obese 97 (25.9) 1.0 0.8-1.1 45 (50.0) 1.5 1.1-2.0 
Income ($)        
 <40,000 30 (85.7) 1.3 1.1-1.5 15 (55.6) 1.5 1.0-2.2 
 40,000+ 301 (68.3) 1  106 (37.2) 1  
 Unknown 46 (61.3) 0.9 0.7-1.1 18 (45.0) 1.2 0.8-1.8 
Clinic        
 Clinic A (no co-test policy) 183 (62.5) 1  62 (36.1) 1  
 Clinic B (co-test policy) 172 (76.4) 1.2 1.1-1.4 67 (41.9) 1.2 0.9-1.5 
 Clinic C (no co-test policy) 22 (66.7) 1.1 0.8-1.4 10 (50.0) 1.4 0.9-2.3 
Married        
 Never 57 (67.9) 1  21 (39.6) 1  
 Divorced/ Widowed 
/Separated 
74 (67.3) 1.0 0.8-1.2 29 (42.0) 1.1 0.7-1.7 
 Married 245 (68.8) 1.0 0.9-1.2 89 (38.9) 1.0 0.7-1.5 
Education        
 High school or less 61 (74.4) 1  18 (32.7) 1  
 Some post high school 77 (68.8) 0.9 0.8-1.1 34 (48.6) 1.5 1.0-2.3 
 College graduate 113 (66.1) 0.9 0.8-1.1 37 (35.2) 1.1 0.7-1.7 
 Post graduate 124 (67.8) 0.9 0.8-1.1 50 (51.7) 1.3 0.8-2.0 
Smoking        
 Never 266 (67.7) 1  96 (38.9) 1  
 Former 74 (67.3) 1.0 0.9-1.2 27 (38.0) 1.0 0.7-1.4 




 Current 35 (76.1) 1.1 0.9-1.3 16 (50.0) 1.3 0.9-1.9 
Menopausal Status        
 Premenopausal 151 (67.4) 1  60 (41.1) 1  
 Perimenopausal 109 (66.1) 1.0 0.9-1.1 42 (41.6) 1.0 0.8-1.4 
 Postmenopausal 106 (71.1) 1.1 0.9-1.2 35 (36.8) 0.9 0.7-1.2 
 Not classified 11 (84.6) 1.3 1.0-1.6 2 (20.0) 0.5 0.1-1.7 
Screening History             
Time Since Last Abnormal Pap (BL)       
 Never abnormal 214 (73.5) 1  90 (44.8) 1  
 0-5 years 31 (50.0) 0.7 0.5-0.9 6 (21.4) 0.5 0.2-1.0 
 6+ years 121 (66.5) 0.9 0.8-1.0 41 (36.3) 0.8 0.6-1.1 
 Unknown 11 (68.8) 0.9 0.7-1.3 2 (20.0) 0.5 0.1-1.6 
Ever Colposcopy (BL)       
 No 299 (71.7) 1  114 (41.0) 1  
 Yes 76  (58.0) 0.8 0.7-1.0 25 (34.7) 0.9 0.6-1.2 
When was last Pap        
 W/in last year 277 (64.1) 1  97 (37.5) 1  
 1-5 years ago 96 (83.5) 1.3 1.2-1.5 40 (44.9) 1.2 0.9-1.6 
 Don't Know 3 (100) 1.6 1.5-1.7 1 (33.3) 1.3 0.5-3.6 
Next Expected Pap        
 Within a year 280 (63.4) 1  96 (36.2) 1  
 Within 2 years 70 (87.5) 1.4 1.2-1.5 27 (43.6) 1.2 0.9-1.7 
 Within 5 years 13 (86.7) 1.4 1.1-1.7 11 (84.6) 2.3 1.8-3.1 
 Don't Know 14 (100) 1.6 1.5-1.7 5 (41.7) 1.2 0.6-2.3 
Risk Factors             
Lifetime Number of Sex Partners (BL)       
 <5 146 (68.2) 1  58 (41.7) 1  
 5+ 229 (68.8) 1.0 0.9-1.1 81 (38.4) 0.9 0.7-1.2 
Recent Sex*        
 No sex 106 (75.7) 1  40 (40.8) 1  
 Yes, no new partner 256 (66.5) 0.9 0.8-1.0 93 (38.9) 1.0 0.7-1.3 
 Yes, new partners 15 (60.0) 0.8 0.6-1.1 6 (40.0) 1.0 0.5-1.9 
HPV Serology at BL        
 Negative 135 (71.1) 1  49 (39.5) 1  
 Positive 183 (66.6) 0.9 0.8-1.1 68 (39.5) 1.0 0.8-1.3 
Research HPV Testing (during study)     
 Always negative 310 (69.2) 1  109 (37.7) 1  
 Ever positive 67 (65.1) 0.9 0.8-1.1 30 (47.6) 1.3 0.9-1.7 
Clinical HPV Testing (during study)     
 Always negative 225 (70.6) 1  87 (41.2) 1  
 Ever positive 20 (76.9) 1.1 0.9-1.4 9 (47.4) 1.1 0.7-1.9 
 Not Tested 128 (63.7) 0.9 0.8-1.0 42 (35.6) 0.8 0.6-1.1 
Pap Abnormality (BL)      
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 No 348 (69.1) 1  131 (40.6) 1  
 Yes 22 (59.5) 0.9 0.7-1.1 7 (31.8) 0.8 0.4-1.5 
Knowledge and Attitudes towards Cervical Cancer Screening & Guidelines 
How often should women have Pap smears?       
 Yearly 260 (63.7) 1  86 (35.0) 1  
 Every other year 62 (83.8) 1.3 1.2-1.5 23 (39.7) 1.1 0.8-1.6 
 Every 3-5 years 34 (97.1) 1.5 1.4-1.7 19 (61.3) 1.8 1.3-2.4 
 More than once a year 9 (42.9) 0.7 0.4-1.1 5 (71.4) 2.0 1.2-3.4 
 Don't know 12 (100) 1.5 1.2-1.7 6 (60.0) 1.7 1.0-2.9 
Aware of the guideline change?       
 No 157 (65.4) 1  60 (40.5) 1  
 Yes 217 (70.9) 1.1 1.0-1.2 77 (38.3) 0.9 0.7-1.2 
 Don't Know 2 (50.0) 0.9 0.5-1.9 1 (50.0) 1.6 0.7-3.8 
Have annual w/o pap        
 No 105 (79.6) 1  43 (43.4) 1  
 Yes 245 (64.1) 0.8 0.7-0.9 82 (36.0) 0.8 0.6-1.1 
 Don't Know 25 (73.5) 0.9 0.7-1.2 14 (60.9) 1.4 0.9-2.1 
Test preference        
 Pap Only 211 (63.4) 1  64 (33.0) 1  
 HPV Only 27 (62.8) 1.0 0.8-1.3 10 (38.5) 1.2 0.7-2.0 
 Either 138 (79.8) 1.3 1.1-1.4 64 (48.9) 1.5 1.1-1.9 
Which is more concerning       
 Abnormal Pap 99 (67.8) 1  35 (37.6) 1  
 HPV Positive 40 (78.4) 1.2 1.0-1.4 14 (38.9) 1.0 0.6-1.7 
 Equally concerning 238 (67.4) 1.0 0.9-1.1 90 (40.4) 1.1 0.8-1.5 
If HPV test only, how much concern about not having a Pap 
smear 
    
 None 103 (85.8) 1  48 (49.5) 1  
 Slight 147 (73.1) 0.9 0.8-1.0 52 (38.0) 0.8 0.6-1.0 
 Moderate 90 (54.6) 0.6 0.5-0.7 29 (34.5) 0.7 0.5-1.0 
 Severe 35 (56.5) 0.7 0.5-0.8 10 (31.3) 0.6 0.4-1.1 
Perceived Risk of Warts     
 None/Low 357 (68.9) 1  132 (39.4) 1  
 Moderate/High 17 (63.0) 0.9 0.7-1.2 5 (35.7) 0.9 0.4-1.9 
Perceived Risk of HPV     
 None/Low 339 (68.9) 1  122 (38.4) 1  
 Moderate/High 38 (66.7) 1.0 0.8-1.2 17 (50.0) 1.3 0.9-1.9 
Perceived Risk of Cervical Cancer     
 None/Low 338 (71.2) 1  119 (37.7) 1  
  Moderate/High 39 (68.7) 0.7 0.6-0.9 20 (55.6) 1.5 1.1-2.0 




Is your primary care provider a(n): 
    
 
Internist/ Family Practitioner 
    
 
Physician's Assistant (PA) 
    
 
Nurse Practitioner 
     
 
Gynecologist 
     
 
Other Medical Specialist 
     
 
No primary care provider 
     
 
Don't know/ can't remember 
    To the best of your knowledge, in the last 5 years have you had a(n)…? (Check all that 
apply) 
 
General health check-up or physical exam 
   
 
Cholesterol test 
     
 
Diabetes screen or blood glucose test 
    
 
Dental exam 
      
 
Clinical breast exam 
     
 
Mammogram 
     When did you have your last Pap smear? 
    
 
Within the last year 
     
 
Within the last 3 years 
     
 
Within the last 5 years 
     
 
Within the last 10 years 
     
 
More than 10 years ago 
     
 
Don't know/ can't remember 
    When do you expect to have your next Pap smear? 
   
 
Within a year 
     
 
Within 2 years 
     
 
Within 5 years 
     
 
More than 5 years from now 
    
 
Am not planning to have another 
    
 
When doctor/ healthcare provider recommends it 
   
 
If I have symptoms 
     
 
Don't know 
      How often do you think a woman your age should have a Pap smear? 
  
 
More than once a year 
     
 
Every other year 
     
 
Every 3-5 years 
     
 
Every 5-10 years 
     
 
Every 10 years or longer 
     
 
Don't know 
      
Supplemental Table S4.1:  Screening Survey Questions 
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The American College of Obstetricians and Gynecologies (ACOG) recently changed 
Pap smear recommendations for screening to every 3 years for healthy woman over age 
30 with a history of 3 consecutive normal Pap smears.  Have you heard about this 
change in guidelines? 
 
No 
      
 
Yes 
      
 
Don't know 
      Would you have a Pap smear every three years (instead of yearly) if your healthcare 
provider recommended it? 
 
No 
      
 
Yes 
      
 
Don't know 
      Why would you have Pap smears yearly instead of every 3 years? (select all that apply) 
 
Early detection 
     
 
Family history 
     
 
Prior history of abnormal Paps 
    
 
Concern for new exposure (partner change) 
   
 
Fear/ anxiety 
     
 
Other, specify _____________ 
    
Studies show that the risk of a pre-cancerous lesion within 5 years of a normal Pap 
result and a negative high-risk HPV test result is nearly 0%.  Would you get screened 
once every 5 years if both your Pap and HPV results were normal? 
 
No 
      
 
Yes 
      
 
Don't know 
      If you were getting a Pap and/or HPV test once every 3-5 years, would you still 
continue to see your gynecologist every year for an annual exam even if you were not 
due for a Pap smear? 
 
No 
      
 
Yes 
      
 
Don't know 
      What would be your primary reason for seeing the GYN if you did not need a Pap test?   
If you could choose to be screened only with a Pap smear or only with an HPV test, 
which would you choose? 
 
Pap smear only 
     
 
HPV test only 
     
 
No difference/ either one 
     Which would cause you more concern and/or anxiety, an abnormal Pap smear or a 
positive HPV result? 
 
Abnormal Pap smear 
     
 
Positive HPV result 
     
 
Equally concerning 
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If guidelines changed and HPV screening was recommended as the primary screen for 
cervical cancer over Pap testing, how much concern or anxiety would you feel about 
not having a Pap test? 
 
No concern or anxiety 
     
 
Slight concern or anxiety 
     
 
Moderate concern or anxiety 
    
 
Severe concern or anxiety 
     What do you think is the chance that you will get an HPV infection in the future? 
 
 
No chance/ low chance 
     
 
Moderate/ high chance 
     What do you think is the chance that you will get genital warts in the future? 
 
 
No chance/ low chance 
     
 
Moderate/ high chance 
     What do you think is the chance that you will get cervical cancer in the future? 
 
 
No chance/ low chance 
     
 
Moderate/ high chance 
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Chapter 5: Conclusion and Future Directions
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Summary of Results: 
 
This dissertation aimed to examine the impact of revised cervical cancer screening 
guidelines on both patients and health care systems.  Updated several times over the last 
decade, newer guidelines continue to emphasize evidence-based medicine and the 
balance between benefits and harms.  As a result, these updates have included 
recommendations for the addition of HPV testing and extending the time between 
screening tests following a normal result.  However, these policy changes have been met 
with anxiety and concern among both patients and providers.  Understanding the patterns 
of acceptance versus reticence to accept evidence-based guidelines by health systems, 
providers, and patients is critical to developing successful strategies for translation into 
routine practice so that we can continue to prevent cervical cancer while minimizing the 
harms associated with screening.   
 
Here we fill some of these knowledge gaps by incorporating both actual cervical cancer 
screening practice data and patient perspectives towards HPV testing and screening 
interval changes through several specific aims: 1) To examine trends in cervical cancer 
screening practices from 2001-2013 in a large academic medical center by a) describing 
the uptake of co-testing in this medical system between and examining the correlates of 
receiving an HPV co-test during this period and b) estimating the length of time until the 
next screening test following either a negative Pap smear alone or a dual negative co-test 
and comparing these times by age, race, and insurance; 2) investigating the correlates of 
reluctance to adhere to revised guidelines, which recommend the addition of HPV testing 




In chapter 2, we used data from the Pathology Data System (PDS) at Johns Hopkins 
Hospital to examine the incorporation of HPV testing into routine cervical cancer 
screening.  We found a steady increase in the proportion of screening tests in women 
aged 30 years and older that included an HPV co-test, from under 10% in 2006 to almost 
80% in mid-2013.  In the earlier years we also saw differences in the percent of women 
being co-tested by age, race, and insurance type; however these differences narrowed 
with time as co-testing became more common overall.  In addition to differences in who 
received co-tests, we found large heterogeneity amongst the clinics in this single medical 
system—some clinics performed essentially no co-testing, while in others co-testing 
approached 90%.  We also saw that clinics with a majority black population seemed to 
have earlier uptake of co-testing.  To determine whether these clinic-level differences and 
the clustering of patients within clinics affected our prevalence estimates, we used 
adjusted multivariate log-binomial models with robust standard errors, and then to 
account for the clustering of observations within clinics, ran the same models with the 
addition of a random-effect variable for clinic.  With the addition of this clinic 
adjustment, almost all significant associations attenuate greatly, with many becoming 
non-significant, showing that the differences by race and insurance were determined at 
the clinic level, not the individual level.   
 
Over the three time periods examined, the proportion of clinics that co-tested over 75% 
of patients increased from under 10% to almost 50%, while the proportion of clinics co-
testing <25% of patients decreased from over 60% to about 20%.  These findings suggest 
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that clinic-wide policies may be important determinants driving clinical practice.  This 
finding is promising as it suggests that a top-down clinic-level intervention may be as 
effective as a more broad target of individual provider behavior change..  (1) 
 
In chapter 3, we used the same PDS data to explore the uptake of newer screening 
guidelines beyond just the addition of HPV testing—we examined the time between 
screening tests for both cytology alone and Pap/HPV co-testing followed the 
recommendation to extend the interval between tests.  Overall, we saw a coinciding 
increase in screening intervals with increasing rates of co-testing, but almost no change in 
screening intervals following cytology alone.  Larger differences in time to next screen 
were seen by age, race and insurance following co-testing than following cytology.  
When median times to next screening test were stratified by both race and ethnicity, a 
somewhat different pattern emerged.  The only significant difference between races for 
co-testing was among women with private insurance.  Initial differences by race were 
also seen among Medicare recipients; however, those racial differences diminished over 
time.  There was also very little difference by race in interval length among women with 
either Medicaid or Tricare insurance with either testing method.  The steepest increase in 
interval length was seen among black and white women with Tricare, increasing by 
almost 2 years during the study period.   
 
Given the effects we saw by age, race, and insurance in co-test uptake (chapter 2), we 
also ran adjusted multivariate cox proportional hazards models determine whether there 
were also differences in screening intervals by age, race, and insurance.  We saw 
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essentially opposite trends for cytology and co-testing.  For cytology, older women had a 
higher hazard of returning compared to younger women and compared to white women 
with private insurance, all other race and insurance groups had a lower hazard of 
returning. At the same time though, for co-testing, older women had a lower hazard 
compared to younger women, and almost all race and insurance categories had higher 
hazards than white women with private insurance.  However, considering the clinic-level 
effects demonstrated in co-test uptake (chapter 2), we also ran the screening interval 
models with the addition of a shared frailty term for clinic, so that records from the same 
clinic are assumed to have the same frailty, which accounts for the clustering of women 
within a clinic. With this adjustment, we found many of the significant differences 
disappeared, though a few remained.  Both black and white women with Medicare 
continued to have a lower hazard ratio following cytology, while black women with 
private insurance or Medicaid continued to have higher hazards.   
 
Overall, these analyses demonstrated that along with an increase in co-testing, there was 
an increase in the median time before the next screening visit following a normal co-test 
result, with intervals increasing from 2006 when broader co-test uptake began through 
mid-2010.  The steady increase in this trajectory suggests that given more follow-up time 
the screening interval may reach three years, which was the recommendation since at 
least 2003.  More time will be needed to see whether the most recent 2012 
recommendation of 5 year intervals after a dual negative co-test is being followed.  These 
guidelines also stated that annual Pap smears were unnecessary and specifically 
recommended against them, and stated that if screening was done by cytology alone, 
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return screening should be every three years.   We saw very little evidence of a 
lengthening interval among who were screened by cytology alone over the last ten years 
in this population, remaining steadily around 1.5 years, suggesting a pattern of continued 
over-screening.  The time to next screening visit following negative cytology is almost a 
year shorter than the recommended 3-years across all races and insurance types.  
Similarly, co-testing is only recommended once every five years, or else any comparative 
benefit is lost, and yet no race or insurance group was screened less often than once every 
three years.  Notably, black women are only being screened approximately every 2 years 
after co-testing by both private insurance and Medicare/Medicaid, which is less than half 
the recommended interval.  This greatly increases the likelihood of false positives and 
negates the high negative predictive value that makes co-testing beneficial.   
 
In chapter 4, we incorporated the patient’s perspective about changing cervical cancer 
screening recommendations using data collected in the HPV in Perimenopause (HIP) 
natural history study of women age 35-60 years.  We compared women who indicated 
willingness versus reluctance to accept primary HPV-only testing or a longer interval 
between cervical cancer screening tests by the following factors: demographics, age, 
health status, cervical cancer screening history, sexual history, perceived HPV and 
cervical cancer risk, and participation in preventive health programs.  This cohort 
provided a unique opportunity to simultaneously evaluate a women’s self-reported 
perceived risk and their actual risk of cervical cancer based on intensive measurement of 
HPV and cervical cancer risk markers over a 2-year period.  In this analysis, we found a 
majority of women were aware that screening recommendations had changed, yet most 
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still believed women should be screened annually.  If recommended by their doctor about 
two-thirds were willing to extend screening to every three years, but only a quarter would 
extend screening to five years.  Most women also expressed a strong preference for Pap 
testing, and many expressed at least moderate concern over having an HPV test without a 
Pap test.  A desire for more frequent care, higher degree of worry and perceived risk, and 
abnormal screening history were all associated with reduced willingness to accept HPV 
testing and longer screening intervals.   
 
Overall we found a majority of study participants indicate a willingness to adopt a 
cervical cancer screening strategy of cytology alone or Pap-HPV co-testing every 3 years 
if recommended by their physician, but remain concerned about primary HPV testing and 
co-testing with 5-year screening intervals.  Our results suggest continued reticence to 
accepting newer HPV-based screening algorithms among routinely screened women over 
age 35.  This observation is especially relevant in light of the recent FDA approval of one 
HPV test for an indication of primary cervical cancer screening (2) and that future US 
guideline revisions are likely to consider recommendations for primary screening using 
HPV testing, especially given the transition to primary HPV screening by other large 
national screening programs such as those in Australia (3) and the United Kingdom (4).  
These results suggest that educational interventions to communicate risks associated with 
alternative screening test results are needed in order for women to understand alternative 
screening choices, and contribute to a significant gap in the evidence regarding patient 
perceptions of benefits and harms of screening, which have been underrepresented in 




Public Health Implications: 
 
The findings of this dissertation highlight several important considerations when 
translating updated evidence-based cervical cancer screening guidelines into routine 
practice.  Themes of communication, education, and the need for large-scale policies re-
appeared throughout this research.   
 
Through our work on this study, we had heard anecdotally from both patients and 
providers about some of these issues.  Clinicians mentioned that they weren’t extending 
screening intervals because their patients wouldn’t accept them, while many patients said 
they were unaware that screening recommendations had even changed from annual Pap 
smears.  If patients and clinicians aren’t communicating about the changes, it will be hard 
to break this cycle, though first the guidelines must be effectively communicated from 
those who make them to those for whom they are intended.  It is important that both 
patients and providers are clearly educated about why the guidelines changed, how they 
were determined, and what the clinical implications are, so that both parties can feel 
comfortable with the changes.  This research also demonstrates the importance of buy-in 
from all parties affected by screening guidelines.  Going forward, we believe that 
assessing patient and provider attitudes and concerns and refining recommendations prior 
to publicizing changes would be a critical step in easing the transition to such changes.   
 
Another important finding resulting from this research was the potential influence of 
clinic-level practices in determining what screening guidelines would be followed by 
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individual physicians.  Within a single academic medical system, we found tremendous 
variability in rates of co-testing and screening intervals by clinic.  In one instance for 
example, we did find that a clinic that adopted a clinic-wide policy had relatively quick 
and complete uptake of HPV co-testing (1), (Chapter 3).  Additionally, women in this 
clinic with a uniform co-testing policy were slightly more likely to accept extended 
intervals (Chapter 2).  Taken together, these results support the idea that a top-down 
approach to determining routine practice—both at the clinic-level and perhaps even a 
system-wide level – may be more effective than targeting behavioral interventions to 
individual physicians.  This would, however, still require sufficient education of patients 
and providers with information that specifically addresses their concerns about changing 
screening practice.  The greater and more rapid adoption of extended screening interval 
guidelines by government-funded insurance types, which have changed some of their 
policies to only reimburse screening every two years, also suggests that system-level 
changes in reimbursement coverage are also effective in translation of evidence based 
guidelines to clinical practice.   
 
While this research focused on cervical cancer in particular, many of these findings can 
be applied to future screening guideline revisions for other cancers or health conditions as 
the emphasis towards evidence-based medicine grows.  Recently, there have been 
changes to breast cancer, prostate cancer, and lung cancer screening, and it will be 
important to carefully examine their implementation, uptake, and effectiveness based on 






Although this dissertation addressed several knowledge gaps in the implementation of 
evidence-based screening guidelines, it also uncovered several new questions, some of 
which can only be answered with more time.  For example, we were only able to look at 
data regarding the time between routine negative screens through mid-2010 in order to 
leave at least 3 years for follow-up (the longest recommended interval at that time).  
While we do see evidence of longer time until next screen following a dual negative co-
test, we were unable to look at the effects of the most recent guidelines changes from 
2012.  It will take several more years of follow-up to determine whether Pap intervals are 
being extended to 3 years and co-test intervals to 5 years.  Given the lack of willingness 
to wait 5 years for screening among women in the HIP study, this will be particularly 
important moving forward.  
 
Extending follow-up of the HIP Cohort (or a similar cohort with detailed information on 
attitudes and intentions), with linkage to their medical records, will enable us to 
determine to what extent a woman’s stated intentions match her actual practice.  As 
women were enrolled into our study for 2 years of follow-up, it was not a long enough 
time to accurately assess their screening intervals.  Additionally, our questionnaire asked 
whether woman would be willing to extend intervals or would they feel concerned about 
HPV testing, and while this is important information on it’s own, being able to correlate 
those with a woman’s screening tests and intervals going forward would provide 
additional value.  In addition, incorporating qualitative research into this process will 
provide greater insight into a woman’s response.  Knowing their concerns is an important 
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first step, but in order to address them it is crucial to understand what is motivating their 
beliefs—whether it’s a lack of information, fear, or misunderstanding will help determine 
what type of education or other intervention would be most effective.   
 
An additional piece of information that we were unable to obtain directly was the 
provider’s knowledge of the guidelines and what information they discuss with and 
recommend to their patients.  We used actual screening practice from laboratory records 
as a proxy for clinical practice as it shows the outcome of the interaction between patient 
and provider.  However, this does not capture the entire interaction, and so surveys, 
interviews with physicians, or direct observation of patient-provider discussions would 
provide more detail about what information is conveyed and what questions patients 
express.  This provides an additional opportunity to include a mixed methods approach 
by incorporating a qualitative assessment of a physician’s reaction to and comfort with 
the changing recommendations.   
 
It will also be important to verify our findings using a more representative dataset than 
just women in Baltimore, MD.  For example, a population-based cervical cancer registry, 
such as the New Mexico HPV Pap Registry (NMHPVPR), which has data for all cervical 
cancer screening, diagnosis, and treatment in the state will be a valuable resource to 
determine whether our findings replicate on a larger scale (5).   Another important next 
step is to replicate this analysis using comprehensive electronic medical record data, not 
just laboratory record data as we had access to for this study.  This type of record would 
provide us with much greater information, including all visits a patient had, regardless of 
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whether screening took place, so we could verify women were still in active follow-up.  
Furthermore, these records would contain a woman’s screening history, which would 
provide a denominator for the number of women eligible for extended intervals, and 
demonstrate which high-risk women or women with an abnormal screening history 
should actually be under more frequent follow-up.   
 
As more and more young women are receiving the HPV vaccine, new challenges arise in 
determining the most appropriate way to screen vaccinated women.  While the 
introduction of a primary prevention tool for cervical cancer has been a critical 
development in the fight against cervical cancer, it also raises several new questions and 
concerns about screening in the post-vaccine era.  As intended, the rates of cervical 
cancer will continue to decrease with both vaccination and continued screening; however, 
this reduction in prevalence also reduces the positive predictive value of our screening 
methods, leading to more false positives and all of the follow-ups and procedures that 
may result.  As a result newer screening strategies with alternative testing and triage 
algorithms are being evaluated, and the efficiency of screening becomes an even higher 
priority.    
 
Conclusion: 
Evidence-based recommendations are valuable only if broadly implemented in routine 
clinical and public health practice.  However, key components to effective translation, 
including perceptions and acceptance of screening recommendations by the target 
population, are often absent from the evidence.  We addressed this gap by providing a 
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comprehensive assessment of the uptake of recommendations in a large academic 
medical center and identifying potential patient-specific characteristics, which may affect 
efficient translation. Understanding uptake of new technologies and screening 
recommendations into routine practice is important for streamlining implementation of 
future changes and ensuring healthcare is delivered appropriately and effectively.  
Importantly, these findings are likely applicable across conditions as evidence-based 
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Appendix 1: Kaplan-Meier curves for distribution 






Time to next screening visit (screening interval) was summarized using Kaplan-Meier 
curves, and stratified by several variables, including cytology alone versus co-test, year 





Figure A1.1: Time to next screening test by year and test method 
a)  
b)   
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Figure A1.2: Time to next screening test by age and test method 
 
a)   
 
 b)  
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Figure A1.3: Time to next screening test by race and test method 
 
a)      
 
b)   
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Figure A1.5: Time to next screening test by race/ insurance and test 
method 
 
a)   
 











Appendix 2: Classification and Regression Tree 






As an alternative to traditional regression analyses, we also explored the use of 
Classification and Regression Tree (CART) analysis (non-parametric binary recursive 
partitioning) to determine the variables able to separate our population into distinct 
subgroups of women based on their willingness to extend to five years, three years, or not 
willing to extend at all.  CART analysis provides an alternative way to understand how 
characteristics clustered and predicted willingness than a traditional multivariable 
regression model.  The Gini impurity index was used as the decision criterion for node 
splits in order to minimize misclassification.   After fitting, the tree was pruned using 
cross-validation.  Poisson regression with robust error variance was then used to assess 
correlates of the variables selected by the CART analysis.  Regression analyses were 
carried out in Stata version 13.1 and CART analysis was carried using RStudio version 
0.98.501 and R version 3.1.0.  
 
Classifying women into groups of willingness (CART) 
 
Classification and regression tree (CART) analyses were used to identify subgroups of 
participants within our study and the shared characteristics or beliefs that influence their 
attitudes toward adopting extended intervals for cervical cancer screening.  The final 
pruned classification tree (Figure 1) identified seven variables that best split the study 
population into three groups (those willing to extend to five years, those willing to extend 
to three years only, and those not willing to extend at all).  Three of those variables are 
fixed characteristics (recent sexual activity, age, marital status) and four were based on 
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attitudes and beliefs (concern about not having a Pap smear, expected time until next Pap 
smear, whether a women would still have an annual exam if she wasn’t having a Pap 
smear, and perceived risk of cervical cancer).   The strongest factor predicting whether a 
woman would extend screening to at least three year intervals was if she said not having a 
Pap smear would give her none or only slight anxiety, while those reporting moderate to 
severe anxiety were likely to prefer to continue with annual screening.  Women who 
expected to have their next Pap smear in a year and those who perceived themselves to be 
at a moderate or high risk of developing cervical cancer in the future were also unlikely 
to agree to extended screening intervals.  Younger women and women who had never 
been married were most likely to accept five year screening intervals.   
 
Correlates of Attitude and Belief Variables Selected in CART 
 
We then explored the determinates of the four attitude and belief variables identified as 
determining a woman’s willingness to extend screening, as these could offer insight into 
the development of future education or intervention (Table 1).  Women seemed to have a 
good sense of their personal risk of cervical cancer—former and current smokers were 
more likely to report a moderate or high perceived risk of developing cervical cancer in 
the future compared to women who never smoked (PR: 1.79, 95% CI: 1.10-2.94, PR: 
2.76, 95% CI: 1.60-4.77, respectively), as were obese women (PR: 1.73, 95% CI: 1.03-
2.90), and women with a prior history of abnormal Pap smears (PR: 2.06, 95% CI: 1.31-
3.24) or colposcopies (PR: 1.55, 95% CI: 0.99-2.43).  Likewise, woman with 5 or more 
lifetime sex partners (PR: 1.76, 95% CI: 1.09-2.86) and women who had an abnormal 
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Pap smear during the two years of follow-up (PR: 1.94, 95% CI: 1.05-3.58) reported 
higher perceived risks of cervical cancer.   
 
Those women most concerned about having a primary HPV test instead of a Pap test 
were those with moderate or high perceived risk of cervical cancer (PR: 1.46, 95% CI: 
1.16-1.84), recent abnormal Pap smears (PR: 1.40, 95% CI 1.07-1.82), current smokers 
(PR: 1.68, 95% CI: 1.30-2.17), and those who believed women should have more 
frequent screening (PR: 1.68, 95% CI: 1.29-2.18).  Post-graduate education (PR: 0.70, 
95% CI: 0.52-0.93) and believing that women should have Pap smears less often than 
every year was associated with less concern switching from Pap to HPV testing (every 
other year PR: 0.51, 95% CI: 0.33-0.78, every 3-5 year testing PR: 0.38, 95% CI: 0.18-
0.79).  Women who preferred HPV testing (PR: 0.29, 95% CI: 0.14-0.61) or who didn’t 
have a test preference (PR: 0.71, 95% CI: 0.56-0.89) were less likely to be concerned 
about a change to HPV testing. 
 
Women aged 55-60 were more likely to report an interval of greater than one year before 
they expected to have their next Pap smear (PR: 1.72, 95% CI: 1.00-2.96).   Women who 
were currently or formerly married were more than twice as likely to wait more than a 
year for their next Pap smear than women who had never been married (PR: 2.66, 95% 
CI 1.27-5.60, PR: 2.65, 95% CI: 1.20-5.86).  Women who were aware of the change in 
guidelines at the time of the questionnaire and women seen in the practice that 
implemented routine Pap/HPV co-testing were also twice as likely to wait more than a 
year before their next screen.  Women with a history of abnormal Pap smears (PR: 0.64, 
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95% CI: 0.44-0.91), colposcopies (PR: 0.55, 95% CI: 0.34-0.91) and those who tested 
HPV positive by hc2 (PR 0.30, 95% CI: 0.08-1.15) or did not have a clinical HPV test 
(0.48, 95% CI: 0.31-0.72) during the study were more likely to expect their next Pap 
smear within a year.    
 
Non-white women were more likely to state that they would continue to see their doctor 
for annual exams regardless of whether they were having a Pap smear that year (Black 
PR: 1.14, 95% CI: 1.03-1.28, Other races PR: 1.23, 95% CI: 1.09-1.39).  Similarly, 
women who reported having any concern about changing to primary HPV testing were 
more likely to continue annual exams even without screening.  Current smokers were 










Perceived risk cervical 
cancer 
Concern about no 
Pap smear Next expected pap Annual without Pap 
  
PR CI PR CI PR CI PR CI 
Demographics 
        









40-44 0.92 0.47-1.80 1.51 1.09-2.10 1.06 0.59-1.89 1.02 0.88-1.20 
 
45-49 0.67 0.33-1.34 1.14 81-1.60 1.17 0.69-2.00 1.1 0.96-1.27 
 
50-54 1.36 0.74-2.48 1.2 0.85-1.70 0.74 0.39-1.38 0.94 0.79-1.11 
 
55-60 0.59 0.25-1.38 0.97 0.64-1.47 1.72 1.00-2.96 0.99 0.83-1.18 
Race 











Black 1.21 0.72-2.04 1.34 1.06-1.69 0.67 0.39-1.15 1.14 1.03-1.28 
 
Other 0.38 0.10-1.49 1.26 0.90-1.78 0.83 0.41-1.66 1.23 1.09-1.39 
Income 
         
 











Unknown 1.17 0.64-2.12 1.08 0.82-1.43 1 0.61-1.64 0.99 0.86-1.14 
BMI 











Overweight 1.24 0.72-2.14 1.14 0.90-1.46 1.16 0.78-1.73 0.98 0.88-1.10 
 
Obese 1.73 1.03-2.90 1.26 0.99-1.61 1.15 0.76-1.76 1.04 0.93-1.16 
Clinic 











WM 1.49 0.97-2.30 1.17 0.95-1.44 2.02 1.42-2.85 1.05 0.95-1.16 
 
BV/GCRC/JH
OC 0.8 0.26-2.47 1.19 0.79-1.7 0.42 0.11-1.67 1.06 0.88-1.29 
Married 
         













Div/Wid/Sep 1.39 0.64-2.98 0.92 0.66-1.30 2.65 1.20-5.86 1.03 0.87-1.22 
 
Married 1.3 0.67-2.55 0.99 0.75-1.31 2.66 1.27-5.60 1.05 0.92-1.21 
Education 
         
 










Some post HS 0.83 0.43-1.60 0.89 0.66-1.20 0.69 0.36-1.31 1.01 0.86-1.18 
 
College 
graduate 0.58 0.30-1.11 0.86 0.65-1.13 1.35 0.81-2.24 1 0.87-1.16 
 
Post graduate 0.83 0.46-1.50 0.7 0.52-0.93 0.9 0.52-1.54 0.96 0.83-1.11 
Smoking 











Former 1.79 1.10-2.94 1.26 0.99-1.59 1.09 0.72-1.65 0.97 0.86-1.09 
 
Current 2.76 1.60-4.77 1.68 1.30-2.17 1.01 0.54-1.88 0.78 0.62-0.99 
Menopausal Status 











Peri 1.12 0.68-1.85 0.79 0.62-1.01 1.07 0.71-1.61 0.93 0.83-1.04 
 
Post 1.04 0.61-1.77 0.9 0.71-1.14 1.15 0.76-1.73 0.9 0.80-1.01 
 
Not Classified 0.59 0.09-1.02 0.5 0.18-1.36 0.82 0.22-3.03 0.77 0.50-1.18 
          Screening History 
        Ever Abnormal Pap (BL) 











Yes 2.07 1.32-3.24 1.11 0.91-1.36 0.64 0.44-0.91 0.98 0.89-1.08 
Time Since Last Abn (BL) 
        
 









0-5 years 2.02 1.05-3.86 1.4 1.07-1.82 0.34 0.14-0.81 1.01 0.87-1.17 
 
6+ years 2.1 1.31-3.38 1.03 0.82-1.30 0.76 0.53-1.11 0.97 0.87-1.08 
 
Don't know 2.1 0.71-6.21 0.95 0.50-1.83 0.53 0.14-1.96 1.06 0.83-1.35 
 
 151 
Ever Colpo (BL) 











Yes 1.55 0.99-2.43 1.21 0.98-1.50 0.55 0.34-0.91 0.88 0.78-1.00 
When was last pap 
        
 









1-5 years ago 1.01 0.79-1.28 0.81 0.46-1.42 1.55 1.08-2.24 0.92 0.81-1.05 
 
Don't Know 0.8 0.16-4.00 -- -- 3.84 1.68-8.78 0.86 0.39-1.93 
Next Expected Pap 
        
 
Within a year 1 
 
1 














Don't Know 1.6 0.57-4.48 1 0.54-1.85 
  
1.14 0.91-1.42 
          Knowledge and Attitudes towards Cervical Cancer Screening & Guidelines 
    How often should women have a Pap smear 












year 0.53 0.24-1.18 0.51 0.33-0.78 2.51 1.70-3.72 0.96 0.83-1.11 
 
Every 3-5 
years 0.37 0.09-1.45 0.38 0.18-0.79 3.69 2.46-5.51 0.93 0.74-1.16 
 
More than 
once a year 0.65 0.17-2.46 1.68 1.29-2.18 0.68 0.18-2.61 1.25 1.12-1.40 
 
Don't know 0.54 0.08-3.58 0.55 0.21-1.48 3.58 1.93-6.62 0.91 0.63-1.31 
Aware of the guideline change? 











Yes 0.76 0.50-1.17 0.93 0.76-1.38 2.16 1.46-3.20 1.08 0.98-1.19 
 
Don't Know 1.61 0.29-9.06 1.17 0.43-3.14 -- -- 0.55 0.19-1.61 
Have annual w/o pap 











Yes 1.41 0.82-2.45 1.23 0.96-1.58 1.2 0.79-1.80 
  
 
Don't Know 0.83 0.25-2.73 0.56 0.30-1.13 0.16 0.02-1.16 
  Test preference 
        
 









HPV Only 0.55 0.18-1.70 0.29 0.14-0.61 1.16 0.62-2.17 0.9 0.73-1.11 
 
Either 1.33 0.86-2.06 0.71 0.56-0.89 1.28 0.90-1.83 1 0.90-1.10 
Which is more concerning 
       
 









HPV Pos 1.15 0.47-2.79 0.46 0.24-0.86 1.33 0.75-2.36 0.9 0.71-1.13 
 
Equally 
concerning 1.5 0.86-2.52 1.19 0.94-1.51 1 0.68-1.49 1.12 0.99-1.25 
If HPV test only, how much concern 
       
 
None 1 






Slight 4.18 1.50-11.63 
  
1.14 0.74-1.78 1.17 1.01-1.35 
 
Moderate 5.09 1.83-14.14 
  
0.91 0.56-1.48 1.14 0.98-1.33 
 
Severe 7 2.41-20.37 
  
0.73 0.36-1.47 1.28 1.08-1.50 
Perceived Risk of Warts 











Moderate/High 3.89 2.39-6.33 0.81 0.47-1.39 0.73 0.29-1.84 1.13 0.96-1.33 
Perceived Risk of HPV 











Moderate/High 3.41 2.23-5.22 0.98 0.70-1.36 0.59 0.29-1.21 1.05 0.91-1.21 
Perceived Risk of Cervical Cancer 













1.46 1.16-1.84 1.02 0.63-1.67 1.08 0.96-1.22 
          Risk Factors 
        Lifetime Sex Partners 













5+ 1.76 1.09-2.86 1.21 0.98-1.50 0.92 0.66-1.30 0.91 0.83-1.00 
Recent Sex 
        
 









Yes, no new 
partner 1.09 0.65-1.82 0.98 0.78-1.24 1.03 0.69-1.52 1.04 0.93-1.17 
 
Yes, new 
partners 1.3 0.48-3.54 1.16 0.74-1.83 0.61 0.20-1.87 1.14 0.94-1.40 
HPV Serology at BL 











Pos 1.3 0.81-2.09 1.04 0.84-1.30 0.87 0.61-1.25 0.99 0.90-1.10 
HPV Status (during study) 











Pos 1.51 0.94-2.44 1.02 0.79-1.32 0.8 0.50-1.29 1.03 0.91-1.15 
Observed Pap Abnormality 











Yes 1.94 1.05-3.58 1.18 0.84-1.67 0.13 0.02-0.89 0.92 0.74-1.14 
Clinical HPV Testing 











Positive 1.15 0.45-2.96 0.51 0.25-1.04 0.3 0.08-1.15 0.74 0.54-1.03 
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EDUCATION AND TRAINING 
 
2011- 2014: PhD, Department of Epidemiology, Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD 
Dissertation: When Less is More: Understanding Factors Influencing Patient and 
Provider Attitudes and Behavior When Cervical Cancer Screening Guidelines 
Recommend Less Frequent Screening 
 
2009: Masters of Science (ScM) in Epidemiology, Concentration: Infectious Disease, 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
Thesis: Association between latent herpesviruses and acetowhitening in cervical cancer 
screening 
 
2007: Bachelor of Arts (BA) in Human Biology, Concentration in Immunology, 




07/09- present: Senior Research Assistant & Data Manager, HIP (HPV in 
Perimenopause) Study, Department of Epidemiology, Johns Hopkins School of Public 
Health, Baltimore, MD 
• Create and manage databases, including data checking and data cleaning 
• Develop study documentation (protocols, forms, questionnaires)  
• Conduct interviews with study participants 
• Prepare and analyze data 
• Contribute to writing manuscripts  
 
11/11-present: Research Assistant, Project SEARCH: Research to Prevention (R2P)- 
Concurrency Validity Study, South Africa, Department of Epidemiology, Johns Hopkins 
School of Public Health, Baltimore, MD 
• Data entry and data management 






5/13-7/13: Research Assistant, myHPV: Malaysian HPV Prevalence Study, Johns 
Hopkins School of Public Health & Perdana University, Kuala Lumpur, Malaysia 
• Prepare IRB and Ethics approval applications 
• Develop study materials including protocols, consents, questionnaires, and data 
collection and management systems 
• Site development and preparation for study, including staff training and piloting of 
interviews, sample collection 
 
06/12-08/12: Research Assistant, MP3 Combination HIV Prevention for MSM in 
Southern Africa, Center for Global Health, Johns Hopkins School of Public Health, Port 
Elizabeth, South Africa 
Global Health Established Field Placement Award 
• Site development and preparation for study, including staff training and development of 
recruitment and retention plans 
• Community engagement and establishment of a community advisory board 
 
03/08- 05/09: Research Assistant, Gravitt Lab, Department of Epidemiology, Johns 
Hopkins School of Public Health, Baltimore, MD  
• Performed Hybrid Capture and Real Time PCR assays to test for HPV and other viral 
infections  
• Performed manual DNA extractions and gel electrophoresis  
• Data entry and data analysis using ACCESS & STATA 
 
06/05-08/05, 06/06-08/06: Intern, Health Research Training Program- Department of 
Health, New York City, NY             
Office of Intergovernmental Affairs (‘05) 
• Reviewed and tracked City and State legislation and served as liaison between Dept. of 
Health and local elected officials 
• Assisted on West Nile Virus Steering Committee  
• Trained to assist in outbreak investigations of communicable diseases 
Bureau of STD Control (’06): Study titled “Knowledge, Attitudes, and Practices of 
College Students: Sex, Drugs, and Alcohol” 
• Designed survey questionnaire and authored literature review, background, methods 
and procedures 
• Drafted IRB and grant applications  
• Selected to present study methodology and procedures to all interns and preceptors 
 
HONORS AND AWARDS 
 
2014: Carol Eliasberg Martin Scholarship in Cancer Prevention, Johns Hopkins School of 
Public Health 
 







2013: Meyerhoff Fellowship in Cancer Prevention Award, Department of Epidemiology, 
Johns Hopkins School of Public Health 
 
2012-2013: Dissertation Research Fund Award, Department of Epidemiology, Johns 
Hopkins School of Public Health 
 
2012: Student Assembly Conference Fund Award, Johns Hopkins School of Public 
Health 
 
2012: National Cancer Institute Conference Travel Award, 28
th
 Annual Papillomavirus 
Society, San Juan, Puerto Rico 
 
2012: Global Health Established Field Placement Award- South Africa, Center for Global 
Health, Johns Hopkins School of Public Health 
 
2012: Carol Eliasberg Martin Scholarship in Cancer Prevention, Johns Hopkins School of 
Public Health 
 
2012: Meyerhoff Fellowship in Cancer Prevention Award, Department of Epidemiology, 
Johns Hopkins School of Public Health 
 
2011-2014: Departmental Tuition Support, Department of Epidemiology, Johns Hopkins 
School of Public Health 
 
2008: Partial Tuition Scholarship Awarded to Top Students in the Masters Class, 




1. Silver, MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravit PE. Women express 
concern about HPV testing and 5-year intervals in routine cervical cancer screening.  
Obestrics and Gynecology.  In press Nov. 2014.  
 
2. Low HC, Silver MI, Brown BJ, Leng CY, Blas MM, Gravitt PE, Woo YL. 
Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) Linear 
Array for HPV genotyping in anal swab samples. J Clin Microbiol. Dec 2014.   
 
3. Rositch AF, Silver MI, Gravitt PE. Cervical cancer screening in older women: new 
evidence and knowledge gaps. PLoS Medicine. Jan 2014;11(1).  
 
4. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver M, Viscidi RP, 
Burke AE, Ravel J, Gravitt PE. Association between the vaginal microbiota, 
menopause status and signs of vulvovaginal atrophy. Menopause. Oct 2013.   
 
5. Liu SH, Rositch AF, Viscidi RP, Silver MI, Burke A, Gravitt PE. Obesity and HPV 






6. Gravitt PE, Rositch AF, Silver MI, Marks M, Chang K, Burke AE, Viscidi RP. A 
cohort effect of the sexual revolution may be masking an increase in HPV detection at 
menopause in the U.S. JID. Jan 2013;207(2)272-80.  
 
7. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of 
recent and past sexual partnerships on incident human papillomavirus detection: 
acquisition and reactivation in older women. Cancer Res. Dec 2012;72(23):6183-90.  
 
8. Rositch AF, Silver MI, Burke A, Viscidi R, Chang K, Duke CM, Shen W, Gravitt 
PE. The correlation between HPV and abnormal cervical cytology differs by age 
among mid-adult women. J Low Genit Tract Dis.  Jan 2013;17(1):38-47. 
 
9. Marks M, Viscidi R, Chang K, Silver M, Burke AE, Howard L, Gravitt P. 
Differences in the concentration and correlation of cervical immune markers among 
HPV positive and negative perimenopausal women.  Cytokine.  Dec 2011 56(3):798-
803. 
 
10. Silver MI, Paul P, Sowjanya P, Ramakrishna G, Vedantham H, Basany, K, Shah KV, 
Gravitt PE. Shedding of Epstein-Barr virus and cytomegalovirus from the genital tract 
of women in a peri-urban community in Andhra Pradesh, India.  J Clin Microbiol. 
July 2011 49(7):2435-9. 
 
11. Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna BP, Vidyadhari K, Mrudula 
S, Ronnett BM, Vijayaraghavan K, Ramakrishna G, Sowjanya P, Laxmi S, Shah KV, 
Gravitt PE; CATCH Study Team. Determinants of VIA (Visual Inspection of the 
Cervix After Acetic Acid Application) Positivity in Cervical Cancer Screening of 
Women in a Peri-Urban Area in Andhra Pradesh, India. Cancer Epidemiol 















09/13-10/13, 09/14-10/14: Teaching Assistant: Practical Skills in Conducting Research 
in Clinical Epidemiology and Investigation, Department of Epidemiology, Johns 
Hopkins School of Public Health, Baltimore, MD 
 
01/12-03/12, 01/13-03/13: Teaching Assistant: Professional Epidemiology Methods I, 
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 
 
09/08-10/08: Teaching Assistant: Statistical Methods in Public Health I, Department of 
Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD 
 
7/08-08/08: Teaching Assistant: Principles of Epidemiology, Department of 
Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 
 
RESEARCH GRANT PARTICIPATION 
 
2013-2014: R36 Dissertation Research Award  (Principal Investigator) 
Agency for Healthcare Research and Quality (AHRQ)- R36 HS022199-01A1 




2012- present: Member, Surveillance and Outbreak Response Team (SORT), Department 
of Epidemiology & Baltimore City Department of Health 
 
09/2012-present: Member, Optimizing Cancer Screening working group, Sidney Kimmel 
Comprehensive Cancer Center 
 





1. Silver MI, Rositch AF, Phelan-Emrick D, Gravitt PE. Cervical cancer screening 
patterns in the Johns Hopkins Hospital system.  Poster presented at the International 






2. Silver MI, Rositch AF, Burke AE, Viscidi RP, Chang K, Gravitt PE. Patient attitudes 
towards extending cervical cancer screening intervals.  Poster presented at the Society 
for Epidemiologic Research Conference, Seattle, WA, June 2014. 
 
3. Silver MI, Phelan-Emrick D, Gravitt PE. Cervical cancer screening patterns in the 
Johns Hopkins Hospital system.  Poster presented at the Society for Epidemiologic 
Research Conference, Seattle, WA, June 2014. 
 
4. Silver MI, Rositch AF, Burke AE, Viscidi RP, Chang K, Gravitt PE. Patient attitudes 
towards extending cervical cancer screening intervals.  Poster presented at the JHSPH 
Cancer Epidemiology Prevention and Control Trainee Symposium, Baltimore, MD, 
May 2014. 
 
5. Zelaya CE, Silver MI, Go VF, Robertson G, Davis W, Gray G, Celentano DD. 
Improving the validity of the measurement of self-reported sexual concurrency in 
South Africa.  Poster presented at the International AIDS Society Conference, Kuala 
Lumpur, Malaysia, July 2013.  
 
6. Silver MI, Rositch AF, Burke AE, Viscidi RP, Chang K, Gravitt PE. When less is 
more: understanding factors influencing patient attitudes and behavior when cervical 
cancer screening guidelines recommend less screening.  Poster presented at the 
JHSPH Cancer Epidemiology Prevention and Control Trainee Symposium, 
Baltimore, MD, May 2013. 
 
7. Silver MI, Rositch AF, Burke AE, Viscidi RP, Chang K, Gravitt PE. When less is 
more: understanding factors influencing patient attitudes and behavior when cervical 
cancer screening guidelines recommend less screening.  Poster presented at the 
International Papillomavirus Conference, San Juan, Puerto Rico, December 2012.   
 
8. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. The contribution 
of recent and past sexual partnerships on incident HPV detection: acquisition and 
reactivation in older women. Poster presented at the International Papillomavirus 
Conference, San Juan, Puerto Rico, December 2012.   
 
9. Soong TR, Burke AE, Viscidi R, Silver MI, Chang K, Gravitt PE. Evaluating the 
association between hormonal contraceptive use with HPV detection in pre- and 
perimenopausal women in the US. Poster presented at the International 
Papillomavirus Conference, San Juan, Puerto Rico, December 2012.   
 
10. Fakhry C, Viscidi R, Chang K, Silver M, Burke A, Gravitt P. Racial differences in 
the serologic response to HPV.  Poster presented at the International Papillomavirus 
Conference, San Juan, Puerto Rico, December 2012.   
 
11. Rositch AF, Silver MI, Burke AE, Viscidi RP, Chang K, Duke CM, Shen W, Gravitt 





by age among perimenopausal women. Presented at NAMS Annual Meeting, 
Orlando, FL, Oct 2012. 
 
12. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of 
recent and past sexual partnerships on incident human papillomavirus detection: 
acquisition and reactivation in older women.  Presented at NAMS Annual Meeting, 
Orlando, FL, Oct 2012. 
 
13. Silver MI. When less is more: understanding factors influencing patient and provider 
attitudes and behavior when guidelines recommend less frequent cervical cancer 
screening.  Poster presented at the JHSPH Cancer Epidemiology Prevention and 
Control Trainee Symposium, Baltimore, MD, May 2012. 
 
14. Marks M, Burke A, Chang K, Silver M, Howard L, Viscidi R, Gravitt P. Distinct 
cervical immune marker patterns in older HPV positive women.  Poster presented at 
the International Papillomavirus Conference, Berlin, Germany, September 2011. 
 
15. Gravitt PE, Silver M, Rositch AF, Chang K, Marks M, Howard R, Eby Y, Burke A, 
Viscidi R. Cohort effects, sexual behaviors, and HPV prevalence in perimenopausal 
women.   Presented at the International Papillomavirus Conference, Berlin, Germany, 
September 2011. 
 
16. Fakhry C, Silver M, Gravitt P, Viscidi R, Burke A, Chang K, Hackett L, Seay E. 
Associations between race, sexual behaviors, and HPV serostatus.  Presented at the 
International Papillomavirus Conference, Berlin, Germany, September 2011. 
 
17. Duke CM, Shen W, Chang K, Silver M, Viscidi R, Burke A, Gravitt PE. There is a 
Sustained Decrease in Pap Smear and HPV Concordance with Increasing Age: When 
Should we Stop Screening the Low Risk Perimenopausal Patient? Presented at 
NAMS Annual Meeting, Washington, DC, September 2011.   
 
18. Gravitt PE, Chang K, Shen W, Silver M, Viscidi R, Howard R, Burke A. New sex 
partners and menopausal stage are predictors of prevalent HR-HPV in women aged 
35-60 years.  Poster presented at the International Papillomavirus Conference, 
Montreal, Canada, July 2010.     
 
19. Gravitt PE, Vakkalanka P, Chang K, Burke A, Silver M, Silver B, Shen W, Viscidi 
R. High HPV seroprevalence in perimenopausal women attending routine GYN care 
in Baltimore, MD.  Poster presented at the International Papillomavirus Conference, 




10/11-present: Alumni Interviewer, STANFORD UNIVERSITY 






09/07- present: CAMP KESEM NATIONAL   
Camp Kesem is a student-run overnight camp for children whose parents have or had 
cancer. It provides a safe camp environment for kids to relax, have fun, and deal with 
grief and other emotional issues with a supportive staff and other children going through 
similar situations.   
 
Alumni Leadership Board, Camp Kesem National (’14-present) 
Advisory Board Member, Camp Kesem Johns Hopkins (’11-present) 
Camp Director- Michigan, UCLA, George Washington University, Berkeley, Johns 
Hopkins University (’07-’12) 
• Drive organization’s future through participation in monthly leadership calls 
• Liaison between campuses and alumni to provide support in programming, fundraising, 
community outreach, and other camp issues 
• Create reference manual to provide guidance and advice for students as they plan camp 
• Assist in execution of large-scale fundraising efforts 
• Mentor and serve as a resource for student leadership during the year and at camp 
• Oversee all counselors and campers during the week of camp 
• Execute crisis management best practices to ensure the safety of campers and staff 
• Serve as subject matter expert to resolve critical staff and camper issues (behavioral, 
health, etc.)  
 
06/05- 06/07: CAMP KESEM, Stanford University, Stanford, CA 
Administration & Programming Coordinator (2006-2007) 
• Planned and coordinated all programming for 60 counselors and 105 campers for the 
week of camp, including camp structure, scheduling, designing special activities, and 
documents for insurance and emergency procedures  
• Created and maintained camp budget of $125,000 and assisted on fundraising efforts for 
this budget 
 
 
